Document and Entity Information
Document and Entity Information - shares | 3 Months Ended | |
Jun. 30, 2020 | Aug. 13, 2020 | |
Document and Entity Information [Abstract] | ||
Entity Registrant Name | CHINA JO-JO DRUGSTORES, INC. | |
Entity Central Index Key | 0001413263 | |
Amendment Flag | false | |
Current Fiscal Year End Date | --03-31 | |
Document Type | 10-Q | |
Document Period End Date | Jun. 30, 2020 | |
Document Fiscal Period Focus | Q1 | |
Document Fiscal Year Focus | 2020 | |
Entity Filer Category | Non-accelerated Filer | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Small Business | true | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 37,961,790 | |
Entity File Number | 001-34711 | |
Entity incorporate state country code | NV |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets (Unaudited) - USD ($) | Jun. 30, 2020 | Mar. 31, 2020 |
CURRENT ASSETS | ||
Cash and cash equivalents | $ 18,477,212 | $ 16,176,318 |
Restricted cash | 15,095,116 | 14,806,288 |
Financial assets available for sale | 157,644 | 157,159 |
Notes receivable | 28,290 | 57,005 |
Trade accounts receivable | 8,984,595 | 9,770,656 |
Inventories | 11,141,411 | 12,247,004 |
Other receivables, net | 5,599,565 | 5,069,442 |
Advances to suppliers | 2,237,720 | 1,174,800 |
Other current assets | 1,835,927 | 1,528,540 |
Total current assets | 63,557,480 | 60,987,212 |
PROPERTY AND EQUIPMENT, net | 7,095,690 | 7,633,740 |
OTHER ASSETS | ||
Long-term investment | 3,963,758 | 2,544,451 |
Farmland assets | 752,257 | 742,347 |
Long term deposits | 1,447,547 | 1,456,384 |
Other noncurrent assets | 1,049,184 | 1,046,763 |
Operating lease right-of-use assets | 19,351,247 | 21,711,376 |
Intangible assets, net | 3,358,407 | 3,393,960 |
Total other assets | 29,922,400 | 30,895,281 |
Total assets | 100,575,570 | 99,516,233 |
CURRENT LIABILITIES | ||
Short-term bank loan | 2,121,720 | 1,410,130 |
Accounts payable, trade | 16,107,594 | 21,559,494 |
Notes payable | 26,715,374 | 26,605,971 |
Other payables | 2,176,992 | 2,522,330 |
Other payables - related parties | 491,300 | 490,218 |
Customer deposits | 795,903 | 708,140 |
Taxes payable | 328,237 | 119,247 |
Accrued liabilities | 672,469 | 753,612 |
Long-term loan payable-current portion | 2,300,271 | 2,287,742 |
Current portion of operating lease liabilities | 466,213 | 981,090 |
Total current liabilities | 52,176,073 | 57,437,974 |
Long-term loan payable | 3,551,507 | 4,115,958 |
Long-term operating lease liabilities | 16,917,159 | 19,049,575 |
Employee Deposits | 14,145 | 70,507 |
Purchase option and warrants liability | 68,980 | 64,090 |
Total liabilities | 72,727,864 | 80,738,104 |
COMMITMENTS AND CONTINGENCIES | ||
STOCKHOLDERS' EQUITY | ||
Common stock; $0.001 par value; 250,000,000 shares authorized; 37,961,790 and 32,936,786 shares issued and outstanding as of June 30, 2020 and March 31, 2020 | 37,962 | 32,937 |
Preferred stock; $0.001 par value; 10,000,000 shares authorized; nil issued and outstanding as of June 30 and March 31, 2020 | ||
Additional paid-in capital | 63,568,876 | 54,209,301 |
Statutory reserves | 1,309,109 | 1,309,109 |
Accumulated deficit | (36,632,346) | (36,400,837) |
Accumulated other comprehensive income | 1,533,993 | 1,440,424 |
Total stockholders' equity | 29,817,594 | 20,590,934 |
Noncontrolling interests | (1,969,888) | (1,812,805) |
Total equity | 27,847,706 | 18,778,129 |
Total liabilities and stockholders' equity | $ 100,575,570 | $ 99,516,233 |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares | Jun. 30, 2020 | Mar. 31, 2020 |
Statement of Financial Position [Abstract] | ||
Common stock, par value | $ 0.001 | $ 0.001 |
Common stock, shares authorized | 250,000,000 | 250,000,000 |
Common stock, shares issued | 37,961,790 | 32,936,786 |
Common stock, shares outstanding | 37,961,790 | 32,936,786 |
Preferred stock, par value | $ 0.001 | $ 0.001 |
Preferred stock, shares authorized | 10,000,000 | 10,000,000 |
Preferred stock, shares issued | ||
Preferred stock, shares outstanding |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) | 3 Months Ended | |
Jun. 30, 2020 | Jun. 30, 2019 | |
Income Statement [Abstract] | ||
REVENUES, NET | $ 31,054,312 | $ 25,280,784 |
COST OF GOODS SOLD | 23,074,093 | 19,219,346 |
GROSS PROFIT | 7,980,219 | 6,061,438 |
SELLING EXPENSES | 6,272,407 | 5,968,551 |
GENERAL AND ADMINISTRATIVE EXPENSES | 2,120,166 | 2,851,612 |
TOTAL OPERATING EXPENSES | 8,392,573 | 8,820,163 |
LOSS FROM OPERATIONS | (412,354) | (2,758,725) |
OTHER INCOME (EXPENSE): | ||
INTEREST INCOME | 163,588 | 47,873 |
INTEREST EXPENSE | (127,387) | |
OTHER | 50,021 | (62,485) |
CHANGE IN FAIR VALUE OF PURCHASE OPTION AND WARRANTS LIABILITY | (4,890) | 403,555 |
LOSS BEFORE INCOME TAXES | (331,022) | (2,369,782) |
PROVISION FOR INCOME TAXES | 57,570 | 8,388 |
NET LOSS | (388,592) | (2,378,170) |
LESS: NET LOSS ATTRIBUTABLE TO NONCONTROLLING INTEREST | (157,083) | (243,219) |
NET LOSS ATTRIBUTABLE TO CHINA JO-JO DRUGSTORES, INC. | (231,509) | (2,134,951) |
OTHER COMPREHENSIVE LOSS | ||
FOREIGN CURRENCY TRANSLATION ADJUSTMENTS | 93,569 | (405,238) |
COMPREHENSIVE LOSS | $ (295,023) | $ (2,783,408) |
WEIGHTED AVERAGE NUMBER OF SHARES: | ||
Basic | 34,428,271 | 32,453,269 |
Diluted | 34,428,271 | 32,453,269 |
LOSS PER SHARES: | ||
Basic | $ (0.01) | $ (0.07) |
Diluted | $ (0.01) | $ (0.07) |
Condensed Consolidated Statem_2
Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($) | Common Stock | Additional paid-in capital | Retained Earnings Statutory reserves | Retained Earnings Accumulated deficit | Accumulated other comprehensive income/(loss) | Non-controlling interest | Total |
Balance at Mar. 31, 2019 | $ 28,937 | $ 44,905,664 | $ 1,309,109 | $ (30,587,468) | $ 2,508,964 | $ (1,194,039) | $ 16,971,167 |
Balance, Share at Mar. 31, 2019 | 28,936,778 | ||||||
Stock based compensation | 34,560 | 34,560 | |||||
Stock based compensation, Shares | |||||||
Sale of stock and warrants | $ 4,000 | 9,269,077 | 9,273,077 | ||||
Sale of stock and warrants, shares | 4,000,008 | ||||||
Net loss | (2,134,951) | (243,219) | (2,378,170) | ||||
Foreign currency translation loss | (403,620) | (403,620) | |||||
Balance at Jun. 30, 2019 | $ 32,937 | 54,209,301 | 1,309,109 | (32,722,419) | 2,105,344 | (1,437,258) | 23,497,014 |
Balance, Shares at Jun. 30, 2019 | 32,936,786 | ||||||
Balance at Mar. 31, 2020 | $ 32,937 | 54,209,301 | 1,309,109 | (36,400,837) | 1,440,424 | (1,812,805) | 18,778,129 |
Balance, Share at Mar. 31, 2020 | 32,936,786 | ||||||
Exercise of warrants | $ 25 | 77,475 | 77,500 | ||||
Exercise of warrants, shares | 25,000 | ||||||
Sale of stock and warrants | $ 5,000 | 9,282,100 | 9,282,100 | ||||
Sale of stock and warrants, shares | 5,000,004 | ||||||
Net loss | (231,509) | (157,083) | (388,592) | ||||
Foreign currency translation loss | 93,569 | 93,569 | |||||
Balance at Jun. 30, 2020 | $ 37,962 | $ 63,568,876 | $ 1,309,109 | $ (36,632,346) | $ 1,533,993 | $ (1,969,888) | $ 27,847,706 |
Balance, Shares at Jun. 30, 2020 | 37,961,790 |
Condensed Consolidated Statem_3
Condensed Consolidated Statements of Cash Flows (Unaudited0 - USD ($) | 3 Months Ended | |
Jun. 30, 2020 | Jun. 30, 2019 | |
CASH FLOWS FROM OPERATING ACTIVITIES: | ||
Net income | $ (388,592) | $ (2,378,170) |
Adjustments to reconcile net income to net cash used in operating activities: | ||
Bad debt direct write-off and provision | 18,320 | 758,231 |
Depreciation and amortization | 760,540 | 499,175 |
Stock based compensation | 34,560 | |
Change in fair value of purchase option derivative liability | 4,890 | (403,555) |
Accounts receivable, trade | 444,672 | (959,680) |
Notes receivable | 28,824 | 81,326 |
Inventories and biological assets | 1,140,697 | 2,851,652 |
Other receivables | (293,466) | 371,054 |
Advances to suppliers | (952,166) | 242,652 |
Other current assets | (583,285) | (450,042) |
Long term deposit | 13,299 | 58,630 |
Other noncurrent assets | 806 | (8,631) |
Accounts payable, trade | (5,505,493) | (8,968,168) |
Other payables and accrued liabilities | (435,365) | (105,522) |
Customer deposits | 85,379 | 116,398 |
Taxes payable | 182,583 | 95,326 |
Net cash used in operating activities | (5,478,357) | (8,164,764) |
CASH FLOWS FROM INVESTING ACTIVITIES: | ||
Disposal of financial assets available for sale | 14,658 | |
Acquisition of equipment | (10,536) | (210,356) |
Increase intangible assets | (19,474) | (433,111) |
Investment in a joint venture | (1,408,155) | |
Additions to leasehold improvements | (159,272) | (542,734) |
Net cash used in investing activities | (1,597,437) | (1,171,543) |
CASH FLOWS FROM FINANCING ACTIVITIES: | ||
Proceeds from short-term bank loan | 705,585 | |
Repayment of third parties loan | (570,338) | |
Proceeds from notes payable | 14,392,242 | 15,372,260 |
Repayment of notes payable | (14,364,978) | (16,167,012) |
Decrease in Employee Deposits | (56,447) | |
Exercise of warrants | 77,500 | |
Proceeds from equity financing | 9,287,100 | 9,273,077 |
Repayment of other payables-related parties | (460,000) | |
Net cash provided by financing activities | 9,470,664 | 8,018,325 |
EFFECT OF EXCHANGE RATE ON CASH | 194,852 | (277,067) |
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS AND RESTRICTED CASH | 2,589,722 | (1,595,049) |
CASH AND CASH EQUIVALENTS AND RESTRICTED CASH, beginning of period | 30,982,606 | 24,745,202 |
CASH AND CASH EQUIVALENTS AND RESTRICTED CASH, end of period | 33,572,328 | 23,150,153 |
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: | ||
Cash paid for interest | 127,387 | |
Cash paid for income taxes | $ 29,176 |
Description of Business and Org
Description of Business and Organization | 3 Months Ended |
Jun. 30, 2020 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
DESCRIPTION OF BUSINESS AND ORGANIZATION | Note 1 – DESCRIPTION OF BUSINESS AND ORGANIZATION China Jo-Jo Drugstores, Inc. ("Jo-Jo Drugstores" or the "Company"), was incorporated in Nevada on December 19, 2006, originally under the name "Kerrisdale Mining Corporation". On September 24, 2009, the Company changed its name to "China Jo-Jo Drugstores, Inc." in connection with a share exchange transaction as described below. On September 17, 2009, the Company completed a share exchange transaction with Renovation Investment (Hong Kong) Co., Ltd. ("Renovation"), whereby 7,900,000 shares of common stock were issued to the stockholders of Renovation in exchange for 100% of the capital stock of Renovation. The completion of the share exchange transaction resulted in a change of control. The share exchange transaction was accounted for as a reverse acquisition and recapitalization and, as a result, the consolidated financial statements of the Company (the legal acquirer) are, in substance, those of Renovation (the accounting acquirer), with the assets and liabilities, and revenues and expenses, of the Company being included effective from the date of the share exchange transaction. Renovation has no substantive operations of its own except for its holdings of Zhejiang Jiuxin Investment Management Co., Ltd. ("Jiuxin Management"), Zhejiang Shouantang Medical Technology Co., Ltd. ("Shouantang Technology") and Hangzhou Jiutong Medical Technology Co., Ltd ("Jiutong Medical"), Hangzhou Jiuyi Medical Technology Co. Ltd. ("Jiuyi Technology"), its wholly-owned subsidiaries. The Company is an online and offline retailer and wholesale distributor of pharmaceutical and other healthcare products in the People's Republic of China ("China" or the "PRC"). The Company's offline retail business is comprised primarily of pharmacies, which are operated by Hangzhou Jiuzhou Grand Pharmacy Chain Co., Ltd. ("Jiuzhou Pharmacy"), a company that the Company controls through contractual arrangements. On March 31, 2017, Jiuxin Management established a subsidiary, Lin'An Jiuzhou Pharmacy Co., Ltd ("Lin'An Jiuzhou") to operates drugstores in Lin'an City. On January 9, 2020, in order to continue expanding and strengthening its local drugstore network, the Company acquired a local drugstores chain with ten stores at a price of $0.14 (RMB 1). The acquired chain agreed to cease their stores' business and liquidate all of the stores 'accounts after Jiuzhou Pharmacy acquired them. In March 2020, the chain was dissolved and its government insurance reimbursement certificates have been transferred to Jiuzhou Pharmacy. The Company's offline retail business also includes four medical clinics through Hangzhou Jiuzhou Clinic of Integrated Traditional and Western Medicine ("Jiuzhou Clinic") and Hangzhou Jiuzhou Medical and Public Health Service Co., Ltd. ("Jiuzhou Service"), both of which are also controlled by the Company through contractual arrangements. In May 2014, Shouantang Technology established Hangzhou Shouantang Bio-technology Co., Ltd. ("Shouantang Bio"). In May 2016, Shouantang Bio set up and held 49% of Hangzhou Kahamadi Bio-technology Co., Ltd.("Kahamadi Bio"), a joint venture specializing in brand name development for nutritional supplements. In 2018, Jiuzhou Pharmacy invested a total of $741,540 (RMB5,100,000) in and held 51% of Zhejiang Jiuzhou Linjia Medical Investment and Management Co. Ltd ("Linjia Medical"), which operates two new clinics in Hangzhou as of March 31, 2020. On March 29, 2019, Jiuzhou Pharmacy formed and currently holds 51% of the equity of Zhejiang AyiGe Medical Health Management Co., Ltd.("Ayi Health"), which is intended to provide technical support such as IT and customer support to our health management business in the future. The Company currently conducts its online retail pharmacy business through Jiuzhou Pharmacy, which holds the Company's online pharmacy license. On September 10, 2015, Renovation set up Jiuyi Technology to provide additional technical support such as webpage development to our online pharmacy business. In November 2015, the technical support function was transferred back to Jiuzhou Pharmacy, which hosts our online pharmacy. The Company's wholesale business is primarily conducted through Zhejiang Jiuxin Medicine Co., Ltd. ("Jiuxin Medicine"), which is licensed to distribute prescription and non-prescription pharmaceutical products throughout China. Jiuzhou Pharmacy acquired Jiuxin Medicine on August 25, 2011. On April 20, 2018, 10% of Jiuxin Medicine shares were sold to Hangzhou Kangzhou Biotech Co. Ltd. for a total proceeds of $79,625 (RMB 507,760). The Company's herb farming business is conducted by Hangzhou Qianhong Agriculture Development Co., Ltd. ("Qianhong Agriculture"), a wholly-owned subsidiary of Jiuxin Management. Due to the complexity of the cultivation business, Qianhong Agriculture has not grown herbs in the three months ended June 30, 2020. The accompanying consolidated financial statements reflect the activities of the Company and each of the following entities: Entity Name Background Ownership Renovation ● Incorporated in Hong Kong SAR on September 2, 2008 100% Jiuxin Management ● Established in the PRC on October 14, 2008 ● Deemed a wholly foreign owned enterprise ("WFOE") under PRC law ● Registered capital of $14.5 million fully paid 100% Shouantang Technology ● Established in the PRC on July 16, 2010 by Renovation with registered capital of $20 million ● Registered capital requirement reduced by the SAIC to $11 million in July 2012 and is fully paid ● Deemed a WFOE under PRC law ● Invests and finances the working capital of Quannuo Technology 100% Qianhong Agriculture ● Established in the PRC on August 10, 2010 by Jiuxin Management ● Registered capital of RMB 10 million fully paid ● Carries out herb farming business 100% Jiuzhou Pharmacy (1) ● Established in the PRC on September 9, 2003 ● Registered capital of RMB 5 million fully paid ● Operates the "Jiuzhou Grand Pharmacy" stores in Hangzhou VIE by contractual arrangements (2) Jiuzhou Clinic (1) ● Established in the PRC as a general partnership on October 10, 2003 ● Operates a medical clinic adjacent to one of Jiuzhou Pharmacy's stores VIE by contractual arrangements (2) Jiuzhou Service (1) ● Established in the PRC on November 2, 2005 ● Registered capital of RMB 500,000 fully paid ● Operates a medical clinic adjacent to one of Jiuzhou Pharmacy's stores VIE by contractual arrangements (2) Jiuxin Medicine ● Established in PRC on December 31, 2003 ● Acquired by Jiuzhou Pharmacy in August 2011 ● 10% of shares sold On April 20, 2018 ● Registered capital of RMB 10 million fully paid ● Carries out pharmaceutical distribution services VIE by contractual arrangements as a wholly-owned subsidiary of Jiuzhou Pharmacy (2) Jiutong Medical ● Established in the PRC on December 20, 2011 by Renovation ● Registered capital of $2.6 million fully paid ● Currently has no operation 100% Entity Name Background Ownership Shouantang Bio ● Established in the PRC in October, 2014 by Shouantang Technology ● 100% held by Shouantang Technology ● Registered capital of RMB 1,000,000 fully paid ● Sells nutritional supplements under its own brand name 100% Jiuyi Technology ● Established in the PRC on September 10, 2015 ● 100% held by Renovation ● Technical support to online pharmacy 100% Kahamadi Bio ● Established in the PRC in May 2016 ● 49% held by Shouantang Bio ● Registered capital of RMB 10 million ● Develop brand name for nutritional supplements 49% Lin'An Jiuzhou ● Established in the PRC in March 31, 2017 ● 100% held by Jiuxin Management ● Registered capital of RMB 5 million ● Explore retail pharmacy market in Lin'An City 100% Linjia Medical ● Established in the PRC in September27, 2017 ● 51% held by Jiuzhou Pharmacy ● Registered capital of RMB 20 million ● Operates local clinics VIE by contractual arrangements as a controlled subsidiary of Jiuzhou Pharmacy (2) Ayi Health ● Established in the PRC in March 29, 2019 ● 51% held by Jiuzhou Pharmacy ● Registered capital of RMB 10 million ● Provide technical Support for medial service VIE by contractual arrangements as a controlled subsidiary of Jiuzhou Pharmacy (2) (1) Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service had been under the common control of Mr. Lei Liu and Ms. Li Qi, the three shareholders (the "Owners") since their respective establishment dates, pursuant to agreements among the Owners to vote their interests in concert as memorialized in a voting rights agreement. Based on such voting agreement, the Company has determined that common control exists among these three companies. The Owners have operated these three companies in conjunction with one another since each company's respective establishment date. Jiuxin Medicine is also deemed under the common control of the Owners as a subsidiary of Jiuzhou Pharmacy. (2) To comply with certain foreign ownership restrictions of pharmacy and medical clinic operators, Jiuxin Management entered into a series of contractual arrangements with Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service on August 1, 2009. These contractual arrangements are comprised of five agreements: a consulting services agreement, operating agreement, equity pledge agreement, voting rights agreement and option agreement. Because such agreements obligate Jiuxin Management to absorb all of the risks of loss from the activities of Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service, and enable the Company (through Jiuxin Management) to receive all of their expected residual returns, the Company accounts for each of the three companies (as well as subsidiaries of Jiuzhou Pharmacy) as a variable interest entity ("VIE") under the accounting standards of the Financial Accounting Standards Board ("FASB"). Accordingly, the financial statements of Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service, as well as the subsidiaries under the control of Jiuzhou Pharmacy, Jiuxin Medicine and Shouantang Bio are consolidated into the financial statements of the Company. |
Liquidity
Liquidity | 3 Months Ended |
Jun. 30, 2020 | |
Liquidity [Abstract] | |
LIQUIDITY | Note 2 – LIQUIDITY The Company's accounts have been prepared in accordance with the accounting principles generally accepted in the United States of America ("US GAAP") on a going concern basis. The going concern basis assumes that assets are realized and liabilities are extinguished in the ordinary course of business at amounts disclosed in the financial statements. The Company's ability to continue as a going concern depends upon aligning its sources of funding (debt and equity) with its expenditure requirements and repayment of the short-term debts as and when they become due. The drug retail business is a highly competitive industry in the PRC. Several large drugstore chains and a variety of single stores operate in Hangzhou City and Zhejiang Province. In order to increase the Company's competitive advantages and gain more local retail pharmacy market share, from fiscal year 2018, we opened fifty-nine new stores in Hangzhou. As a result, the Company incurred significant incremental expense related to rental, labor hiring and training, and marketing activities. As the retail pharmaceutical market becomes more competitive in recent years, a new store usually cannot make profit in its operation until a year later. In fact, the Company incurred significant expenses with limited incremental revenue in the period it opened new stores. At their openings, except for four stores, almost all of the new stores were without government insurance reimbursement certificates. In fact, it usually takes more than one year for a new store to apply for and obtain the local government insurance reimbursement certificate. As of June 30, 2020, the Company had obtained forty-seven reimbursement certificates for stores opened in fiscal 2018 and thereafter. Historically in a mature store, more than half of the total revenue were collected from the individual customers' government insurance program. The Company is in the process of actively applying certificates for all of its new stores. In the future, as more and more stores obtain certificates, the Company expect its new store revenue to increase and eventually contribute positive operating cash flow. The Company's principal sources of liquidity consist of existing cash, equity financing, bank facilities from local banks as well as personal loans from its principal shareholders if necessary. On April 15, 2019, the Company closed a registered direct offering of 4,000,008 shares of common stock at $2.50 per share with gross proceeds of $10,000,020 from its effective shelf registration statement on Form S-3 pursuant to a Securities Purchase Agreement dated April 11, 2019 (the "2019 Securities Purchase Agreement"), by and among the Company and the investors named therein. On June 3, 2020, the Company closed a registered direct offering of 5,000,004 shares of common stock at $2.00 per share with gross proceeds of $10,000,008 from its effective shelf registration statement on Form S-3 pursuant to a Securities Purchase Agreement dated June 1, 2020 (the "2020 Securities Purchase Agreement"), by and among the Company and the investors named therein. The Company has a credit line agreement from a local bank as displayed in detail in Note 16. As of June 30, 2020, approximately $0.74 million of the aforementioned bank credit line was available for further borrowing. Additionally, Jiuzhou Pharmacy obtained a credit line of approximately $7,175,000 (RMB50,000,000) from Haihui Commercial Factoring (Tianjin) Co. Ltd. ("Haihui Commercial") for three years beginning July 26, 2019. As of June 30, 2020, the full amount has been borrowed from Haihui Commercial. Any borrowing thereunder is guaranteed by a third-party guarantor company, and secured by the Company's assets pursuant to a collateral agreement, as well as personal guarantees of some of its principal shareholders. The Company has also obtained additional government insurance reimbursement certificates for its stores opened in the last two years. As the sales reimbursed from the government account for more than half of sales in a mature store, the certificates may significantly increase the sales of these stores in the next 12 months. Additionally, with the proceeds from the registered direct financing closed on April 15, 2019 and June 3, 2020, and increased credit line, the Company believes it can support its operations for at least the next 12 months. |
Summary of Significant Accounti
Summary of Significant Accounting Policies | 3 Months Ended |
Jun. 30, 2020 | |
Accounting Policies [Abstract] | |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | Note 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of presentation and consolidation The accompanying condensed consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America ("US GAAP"). The consolidated financial statements include the financial statements of the Company, its wholly-owned subsidiaries and VIEs. All significant inter-company transactions and balances between the Company, its subsidiaries and VIEs are eliminated upon consolidation. Consolidation of variable interest entities In accordance with accounting standards regarding consolidation of variable interest entities, VIEs are generally entities that lack sufficient equity to finance their activities without additional financial support from other parties or whose equity holders lack adequate decision making ability. All VIEs with which the Company is involved must be evaluated to determine the primary beneficiary of the risks and rewards of the VIE. The primary beneficiary is required to consolidate the VIE for financial reporting purposes. The Company has concluded, based on the contractual arrangements, that Jiuzhou Pharmacy (including its subsidiaries and controlled entities), Jiuzhou Clinic and Jiuzhou Service are each a VIE and that the Company's wholly-owned subsidiary, Jiuxin Management, absorbs a majority of the risk of loss from the activities of these companies, thereby enabling the Company, through Jiuxin Management, to receive a majority of their respective expected residual returns. Control and common control are defined under the accounting standards as "an individual, enterprise, or immediate family members who hold more than 50 percent of the voting ownership interest of each entity." Because the Owners collectively own 100% of Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service, and have agreed to vote their interests in concert since the establishment of each of these three companies as memorialized in the voting rights agreement, the Company believes that the Owners collectively have control and common control of the three companies. Accordingly, the Company believes that Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service were constructively held under common control by Jiuxin Management as of the time the Contractual Agreements were entered into, establishing Jiuxin Management as their primary beneficiary. Jiuxin Management, in turn, is owned by Renovation, which is owned by the Company. Risks and Uncertainties The operations of the Company are located in the PRC. Accordingly, the Company's business, financial condition, and results of operations may be influenced by political, economic, and legal environments in the PRC, as well as by the general state of the PRC economy. The Company's operations in the PRC are subject to special considerations and significant risks not typically associated with companies in North America and Western Europe. These include risks associated with, among others, the political, economic and legal environment and foreign currency exchange. The Company's results may be adversely affected by changes in the political, regulatory and social conditions in the PRC. Although the Company has not experienced losses from these situations and believes that it is in compliance with existing laws and regulations including its organization and structure disclosed in Note 1, this may not be indicative of future results. The Company has significant cash deposits with suppliers in order to obtain and maintain inventory. The Company's ability to obtain products and maintain inventory at existing and new locations is dependent upon its ability to post and maintain significant cash deposits with its suppliers. In the PRC, many vendors are unwilling to extend credit terms for product sales that require cash deposits to be made. The Company does not generally receive interest on any of its supplier deposits, and such deposits are subject to loss as a result of the creditworthiness or bankruptcy of the party who holds such funds, as well as the risk from illegal acts such as conversion, fraud, theft or dishonesty associated with the third party. If these circumstances were to arise, the Company would find it difficult or impossible, due to the unpredictability of legal proceedings in China, to recover all or a portion of the amount on deposit with its suppliers. Members of the current management team own controlling interests in the Company and are also the Owners of the VIEs in the PRC. The Company only controls the VIEs through contractual arrangements which obligate it to absorb the risk of loss and to receive the residual expected returns. As such, the controlling shareholders of the Company and the VIEs could cancel these agreements or permit them to expire at the end of the agreement terms, as a result of which the Company would not retain control of the VIEs. Use of estimates The preparation of consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. The significant estimates made in the preparation of the accompanying consolidated financial statements relate to the assessment of the carrying values of accounts receivable, advances to suppliers and related allowance for doubtful accounts, useful lives of property and equipment, inventory reserve and fair value of its purchase option derivative liability. Because of the use of estimates inherent in the financial reporting process, actual results could materially differ from those estimates. Fair value measurements The Company establishes a three-level valuation hierarchy of valuation techniques based on observable and unobservable inputs, which may be used to measure fair value and include the following: Level 1 – Quoted prices in active markets for identical assets or liabilities. Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Classification within the hierarchy is determined based on the lowest level of input that is significant to the fair value measurement. The Company's financial assets and liabilities, which include financial instruments as defined by FASB ASC 820, include cash and cash equivalents, restricted cash, financial assets available for sales, accounts receivable, notes receivables, other receivable, accounts payable, notes payable, other payable, long-term debt and derivatives. The carrying amounts of cash and cash equivalents, restricted cash, accounts receivable, notes receivables, and accounts payable are a reasonable approximation of fair value due to the short maturities of these instruments (Level 1). The carrying amount of notes payable approximates fair value based on borrowing rates of similar bank loan currently available to the Company (Level 2) (See Note 16). The carrying amount of Long-term loan payable approximates fair value based on borrowing rates of similar bank loan currently available to the Company (Level 2) (See Note 17).The carrying amount of the Company's derivative instruments is recorded at fair value and is determined based on observable inputs that are corroborated by market data (Level 2) (See Note 21). The carrying amount of the financial assets available for sale is recorded at fair value and is determined based on unobservable inputs (Level 3) (See Note 4). The carrying amount of the employee deposits is recorded at fair value and is determined based on unobservable inputs (Level 3) (See Note 22). Active Market Observable Unobservable Total Cash, cash equivalents and restricted cash $ 33,572,328 - - 33,572,328 Financial assets available for sale - - 157,644 157,644 Account receivable 8,984,595 - - 8,984,595 Notes receivable 28,290 - - 28,290 Other receivable 5,599,565 - - 5,599,565 Accounts payable 16,107,594 - - 16,107,594 Notes payable - 26,715,374 - 26,715,374 Other payable 2,176,992 - - 2,176,992 Long-term loan payable - 5,851,778 - 5,851,778 Employee Deposits - - 14,145 14,145 Warrants liability - 68,980 - 68,980 Total $ 66,469,364 32,636,132 171,789 99,277,285 Revenue recognition Effective March 31, 2018, the Company began recognizing revenue under Accounting Standards Codification ("ASC") Topic 606, Revenue from Contracts with Customers ("ASC 606"), using the modified retrospective transition method. The impact of adopting the new revenue standard was not material to the Company's consolidated financial statements. The core principle of this new revenue standard is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. The following five steps are applied to achieve that core principle: ● Step 1: Identify the contract with the customer ● Step 2: Identify the performance obligations in the contract ● Step 3: Determine the transaction price ● Step 4: Allocate the transaction price to the performance obligations in the contract ● Step 5: Recognize revenue when the company satisfies a performance obligation In order to identify the performance obligations in a contract with a customer, a company must assess the promised goods or services in the contract and identify each promised good or service that is distinct. A performance obligation meets ASC 606's definition of a "distinct" good or service (or bundle of goods or services) if both of the following criteria are met: ● The customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer (i.e., the good or service is capable of being distinct). ● The entity's promise to transfer the good or service to the customer is separately identifiable from other promises in the contract (i.e., the promise to transfer the good or service is distinct within the context of the contract). If a good or service is not distinct, the good or service is combined with other promised goods or services until a bundle of goods or services is identified that is distinct. The transaction price is the amount of consideration to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer, excluding amounts collected on behalf of third parties (for example, some sales taxes). The consideration promised in a contract with a customer may include fixed amounts, variable amounts, or both. Variable consideration is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. The transaction price is allocated to each performance obligation on a relative standalone selling price basis. The transaction price allocated to each performance obligation is recognized when that performance obligation is satisfied, at a point in time or over time as appropriate. The Company's revenue is net of value added tax ("VAT") collected on behalf of the PRC tax authorities with respect to the sales of merchandise. VAT collected from customers, net of VAT paid for purchases, is recorded as a liability in the accompanying consolidated balance sheets until it is paid to the relevant PRC tax authorities. Certain contract liabilities primarily represent the Company's obligation to transfer additional goods or services to a customer for which the Company has received consideration, for example, membership points. The consideration received remains a contract liability until goods or services have been provided to the retail customer. The estimated amount based on accrued membership points was deducted from sales revenue. The following is a discussion of the Company's revenue recognition policies by segment under the new revenue recognition accounting standard: Pharmacy retail sales The physical pharmacies sell prescription drugs, over-the-counter ("OTC") drugs, traditional Chinese medicine, nutritional supplements, medical devices and sundry products. Revenue from sales of prescription medicine at drugstores is recognized when the prescription is filled and the customer picks up and pays for the prescription. Revenue from sales of other merchandise at drugstores is recognized at the point of sale, which is when a customer pays for and receives the merchandise. Usually the majority merchandise, such as prescription and OTC drugs, are not refundable after the customers leave the counter. Returns of other products, such as sundry products, are minimal. Sales of drugs reimbursed by the local government medical insurance agency and receivables from the agency are recognized when a customer pays for the drugs at a store. The Company based on historical experience, a reserve for potential losses from denial of reimbursement on certain unqualified drugs is made to the receivables from the government agency. Additionally, several onsite clinics adjacent to pharmacies provide limited medical services. Revenue from medical services is recognized after the service has been rendered to a customer. As revenue from medical services is minimal compared to pharmacy retail sales, it is included as part of the pharmacy retail sales. The Company deduct the membership rewards directly from the retail revenue, and present such amounts in net sales as opposed to the current reduction of operation expense classification. Membership rewards, usually membership points, are accumulated by customers based on their historical spending levels. The Company has determined that there is an additional performance obligation to those customers at the time of the initial transaction. The customers can then redeem these points against the prices of merchandises they purchase in the future. At the end of each period, unredeemed membership rewards are reflected as a contract liability. Online pharmacy sales The online pharmacy segment sells various health products except for prescription drugs. Revenue from online pharmacy sales is recognized when merchandise is shipped to customers. While most deliveries take one day, certain deliveries may take longer depending on a customer's location. Any loss caused in a shipment will be reimbursed by the Company's courier company. The Company's sales policy allows for the return of certain merchandises without reason within seven days after a customer's receipt of the applicable merchandise. Historically, sales returns seven days after merchandise receipts have been minimal. Wholesale Jiuxin Medicine purchases medicine in quantity and distributes products primarily to local pharmacies and medical products dealers. Revenue from sales of merchandise to non-retail customers is recognized when the merchandise is transferred to customers. Historically, sales returns have been minimal. Disaggregation of Revenue The following table disaggregates the Company's revenue by major source in each segment for the three months ended June 30, 2020 and 2019: For the three months ended June 30 2020 2019 Retail drugstores Prescription drugs $ 7,406,774 $ 5,695,286 OTC drugs 6,818,484 7,240,228 Nutritional supplements 1,347,769 1,231,133 TCM 949,012 1,104,050 Sundry products 422,551 298,198 Medical devices 1,865,884 1,166,093 Total retail revenue $ 18,810,474 $ 16,734,988 Online pharmacy Prescription drugs $ 1,869,643 $ - OTC drugs 1,322,811 1,024,602 Nutritional supplements 221,031 107,194 TCM 23,199 13,681 Sundry products 546,720 438,736 Medical devices 929,430 859,392 Total online revenue $ 4,912,834 $ 2,443,605 Drug wholesale Prescription drugs $ 5,966,148 $ 4,880,491 OTC drugs 915,146 1,074,261 Nutritional supplements 59,841 21,691 TCM 28,967 98,828 Sundry products 2,597 5,682 Medical devices 358,305 21,238 Total wholesale revenue $ 7,331,004 $ 6,102,191 Total revenue $ 31,054,312 $ 25,280,784 Contract Balances Contract liabilities primarily represent the Company's obligation to transfer additional goods or services to a customer for which the Company has received consideration, for example membership points and membership rewards. The consideration received remains a contract liability until goods or services have been provided to the retail customer. The following table provides information about receivables and contract liabilities from contracts with customers: June 30, March 31, Trade receivable(included in accounts receivable, net) $ 8,984,595 $ 9,770,656 Contract liabilities (included in accrued expenses) 1,112,508 1,106,982 Restricted cash The Company's restricted cash consists of cash and long-term deposits in a bank as security for its notes payable. The Company has notes payable outstanding with the bank and is required to keep certain amounts on deposit that are subject to withdrawal restrictions. The notes payable are generally short term in nature due to their short maturity period of six to nine months; thus, restricted cash is classified as a current asset. The following represents a reconciliation of cash and cash equivalents in the Consolidated Condensed Balance Sheets to total cash, cash equivalents and restricted cash in the Consolidated Condensed Statements of Cash Flows as of June 30, 2020 and March 31, 2020: June 30, March 31, Cash and cash equivalents $ 18,477,212 $ 16,176,318 Restricted cash 15,095,116 14,806,288 Cash, cash equivalents and restricted cash $ 33,572,328 $ 30,982,606 Accounts receivable Accounts receivable represents the following: (1) amounts due from banks relating to retail sales that are paid or settled by the customers' debit or credit cards, (2) amounts due from government social security bureaus and commercial health insurance programs relating to retail sales of drugs, prescription medicine, and medical services that are paid or settled by the customers' medical insurance cards, (3) amounts due from non-bank third party payment instruments such as Alipay and certain e-commerce platforms and (4) amounts due from non-retail customers for sales of merchandise. Accounts receivable are recorded at net realizable value consisting of the carrying amount less an allowance for uncollectible accounts, as necessary. In the Company's retail business, accounts receivable mainly consist of reimbursements due from the government insurance bureaus and commercial health insurance programs and are usually collected within two or three months. The Company directly writes off delinquent account balances, which it determines to be uncollectible after confirming with the appropriate bureau or program each month. Additionally, the Company also makes estimated reserves on related outstanding accounts receivable based on historical trends. In the Company's online pharmacy business, accounts receivable primarily consist of amounts due from non-bank third party payment instruments such as Alipay and certain e-commerce platforms. To purchase pharmaceutical products from an e-commerce platforms such as Tmall, customers are required to submit payment to certain non-bank third party payment instruments, such as Alipay, which, in turn, reimburse the Company within seven days to a month. Except for customer returns of sold products, the receivables from these payments instruments are rarely uncollectible. In its wholesale business, the Company uses the aging method to estimate the allowance for anticipated uncollectible receivable balances. Under the aging method, bad debt percentages are determined by management, based on historical experience and the current economic climate, are applied to customers' balances categorized by the number of months the underlying invoices have remained outstanding. At each reporting period, the allowance balance is adjusted to reflect the amount computed as a result of the aging method. When facts subsequently become available to indicate that the allowance provided requires an adjustment, a corresponding adjustment is made to the allowance account as a change in estimate. Advances to suppliers Advances to suppliers consist of prepayments to its vendors, such as pharmaceutical manufacturers and other distributors. Since the acquisition of Jiuxin Medicine, the Company have transferred almost all logistics services of its retail drugstores to Jiuxin Medicine. Jiuzhou Pharmacy only directly purchases certain non-medical products, such as certain nutritional supplements. As a result, almost all advances to suppliers are made by Jiuxin Medicine. Advances to suppliers for its drug wholesale business consist of prepayments to its vendors, such as pharmaceutical manufacturers and other distributors. The Company typically receive products from vendors within three to nine months after making prepayments. The Company continuously monitor delivery from, and payments to, its vendors while maintaining a provision for estimated credit losses based upon historical experience and any specific supplier issues, such as discontinuing of inventory supply, that have been identified. Inventories Inventories are stated at the lower of cost or net realizable value. Cost is determined using the first in first out (FIFO) method. The Company carries out physical inventory counts on a monthly basis at each store and warehouse location. Herbs that the Company farms are recorded at their cost, which includes direct costs such as seed selection, fertilizer, labor costs that are spent in growing herbs on the leased farmland, and indirect costs such as amortization of farmland development cost. All costs are accumulated until the time of harvest and then allocated to harvested herbs costs when the herbs are sold. The Company periodically reviews its inventory and records write-downs to inventories for shrinkage losses and damaged merchandise that are identified. The Company provides a reserve for estimated inventory obsolescence or excess quantities on hand equal to the difference, if any, between the cost of the inventory and its estimated realizable value. Farmland assets Herbs that the Company farms are recorded at their cost, which includes direct costs such as seed selection, fertilizer, and labor costs that are spent in growing herbs on the leased farmland, and indirect costs such as amortization of farmland development costs. Since April 2014, amortization of farmland development costs has been expensed instead of allocated into inventory due to unpredictable future market value of planted gingko trees. All related costs described in the above are accumulated until the time of harvest and then allocated to harvested herbs when they are sold. Property and equipment Property and equipment are stated at cost, net of accumulated depreciation or amortization. Depreciation is calculated on the straight-line method over the estimated useful lives of the assets, taking into consideration the assets' estimated residual value. Leasehold improvements are amortized over the shorter of lease term or remaining lease period of the underlying assets. Following are the estimated useful lives of the Company's property and equipment: Estimated Useful Life Leasehold improvements 3-10 years Motor vehicles 3-5 years Office equipment & furniture 3-5 years Buildings 35 years Maintenance, repairs and minor renewals are charged to expenses as incurred. Major additions and betterment to property and equipment are capitalized. Intangible assets Intangible assets are acquired individually or as part of a group of assets, and are initially recorded at their fair value. The cost of a group of assets acquired in a transaction is allocated to the individual assets based on their relative fair values. The estimated useful lives of the Company's intangible assets are as follows: Estimated Land use rights 50 years Software 3 years L icense Infinite The Company evaluates intangible assets for impairment whenever events or changes in circumstances indicate that the assets might be impaired. Impairment of long lived assets The Company evaluates long lived tangible and intangible assets for impairment, whenever events or changes in circumstances indicate that the carrying value may not be recoverable from its estimated future cash flows. Recoverability is measured by comparing the assets' net book value to the related projected undiscounted cash flows from these assets, considering a number of factors including past operating results, budgets, economic projections, market trends and product development cycles. If the net book value of the asset exceeds the related undiscounted cash flows, the asset is considered impaired, and a second test is performed to measure the amount of impairment loss. There were no fixed assets and farmland assets impaired for the three months ended June 30, 2020 and 2019. Notes payable During the normal course of business, the Company regularly issues bank acceptance bills as a payment method to settle outstanding accounts payables with various material suppliers. The Company records such bank acceptance bills as notes payable. Such notes payable are generally short term in nature due to their short maturity period of six to nine months. Income taxes The Company accounts for income taxes following the liability method pursuant to FASB ASC 740 "Income Taxes". Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the period in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if, based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rate is recognized in income in the period that includes the enactment date. The Company also follows FASB ASC 740, which addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. The Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate settlement. ASC 740 also provides guidance on recognition, classification, interest and penalties on income taxes, accounting in interim periods and requires increased disclosures. As of June 30, 2020 and March 31, 2020, the Company did not have a liability for unrecognized tax benefits. It is the Company's policy to include penalties and interest expense related to income taxes as a component of other expense and interest expense, respectively, as necessary. The Company's historical tax years will remain open for examination by the local authorities until the statute of limitations has passed. Under ASC 740-270, entities calculate the income tax provision for an interim period by distinguishing between elements recognized in the income tax provision through (1) applying an estimated annual effective tax rate (ETR) to a measure of year-to-date operating results referred to as "ordinary income (or loss)," and (2) discretely recognizing specific events (referred to as "discrete items") as they occur. Entities should revise the ETR, as necessary, as of the end of each successive interim period during its fiscal year based on changes to any of these estimates and judgments. The ETR expected to apply for the full fiscal year is applied to year-to-date ordinary income (or loss) at the end of each interim period to compute the year-to-date income tax (or benefit) applicable to ordinary income or loss. Income tax expense (or benefit) related to each discrete item is individually determined and recognized in the interim period when the discrete item occurs. As a result, the income tax provision (or benefit) for an interim period might include elements that apply to ordinary income or loss, as well as elements related to discrete items. Discrete items include significant items that are unusual or that occur infrequently. Determining which items are unusual or infrequent often requires a significant degree of judgment. Under ASC 740-270-30-36, entities subject to income taxes in multiple jurisdictions should apply one overall ETR instead of separate ETRs for each jurisdiction when calculating the interim-period income tax or benefit related to consolidated ordinary income (or loss) for the year-to-date interim period, except in certain circumstances. The income tax provision or benefit for each interim period is the difference between the year-to-date amount for the current period and the year-to-date amount for the prior period. Value added tax Sales revenue represents the invoiced value of goods, net of VAT. All of the Company's products are sold in the PRC and are subject to a VAT on the gross sales price. The VAT rates range up to 17%, depending on the type of products sold. The VAT may be offset by VAT paid by the Company on raw materials and other materials included in the cost of producing or acquiring its finished products. The Company recorded a VAT payable net of payments in the accompanying financial statements. Stock based compensation The Company follows the provisions of FASB ASC 718, "Compensation — Stock Compensation," which establishes accounting standards for non-employee and employee stock-based awards. Under the provisions of FASB ASC 718, the fair value of stock issued is used to measure the fair value of services received as the Company believes such approach is a more reliable method of measuring the fair value of the services. For non-employee stock-based awards, fair value is measured based on the value of the Company's common stock on the date that the commitment for performance by the counterparty has been reached or the counterparty's performance is complete. The fair value of the equity instrument is calculated and then recognized as compensation expense over the requisite performance period. For employee stock-based awards, share-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense with graded vesting on a straight–line basis over the requisite service period for the entire award. Advertising and promotion costs Advertising and promotion costs are expensed as incurred and amounted to $77,068 and $80,049 for the three months ended June 30, 2020 and 2019, respectively. Such costs consist primarily of print and promotional materials such as flyers to local communities. Foreign currency translation The Company uses the United States dollar ("U.S. dollars" or "USD") for financial reporting purposes. The Company's subsidiaries and VIEs maintain their books and records in their functional currency the Renminbi ("RMB"), the currency of the PRC. In general, for consolidation purposes, the Company translates the assets and liabilities of its subsidiaries and VIEs into U.S. dollars using the applicable exchange rates prevailing at the balance sheet date, and the statements of income and cash flows are translated at average exchange rates during the reporting period. As a result, amounts related to assets and liabilities reported on the statement of cash flows will not necessarily agree with changes in the corresponding balances on the balance sheet. Equity accounts are translated at historical rates. Adjustments resulting from the translation of the financial statements of the subsidiaries and VIEs are recorded as accumulated other comprehensive income. The balance sheet amounts, with the exception of equity, at June 30, 2020 and at March 31, 2020 were translated at 1 RMB to 0.1414 USD and at 1 RMB to 0.1410 USD, respectively. The average translation rates applied to income and cash flow |
Financial Assets Available for
Financial Assets Available for Sale | 3 Months Ended |
Jun. 30, 2020 | |
Financial Assets Available for Sale [Abstract] | |
FINANCIAL ASSETS AVAILABLE FOR SALE | Note 4 – FINANCIAL ASSETS AVAILABLE FOR SALE As of June 30, 2020 and March 31, 2020, financial assets available for sale amounted to $157,644 (RMB 1,114,500) and $157,159 (RMB 1,114,500), respectively. As of June 30, 2020, the fair value of an investment in a limited partner (LP) in a private equity fund (PE fund), which is intended to invest in retail pharmaceutical business, is $72,551 (RMB514,500). Additionally, the Company has invested in Inner Mongolia Songlu Pharmaceutical Co.("Songlu Pharmaceutical"). As of June 30, 2020, the fair value of the investment is $84,608 (RMB600,000), which accounts for 0.5% shares of Songlu Pharmaceutical. |
Trade Accounts Receivable
Trade Accounts Receivable | 3 Months Ended |
Jun. 30, 2020 | |
Receivables [Abstract] | |
TRADE ACCOUNTS RECEIVABLE | Note 5 – TRADE ACCOUNTS RECEIVABLE Trade accounts receivable consisted of the following: June 30, March 31, Accounts receivable $ 11,378,909 $ 12,034,726 Less: allowance for doubtful accounts (2,394,314 ) (2,264,070 ) Trade accounts receivable, net $ 8,984,595 $ 9,770,656 For the three months ended June 30, 2020 and 2019, $26,834 and $36,068 in accounts receivable were directly written off, respectively. As of June 30, 2020, $515,771 were pledged as collateral for borrowings from financial institutions. As of March 31, 2020, $627,055 were pledged as collateral for borrowings from financial institutions. |
Other Current Assets
Other Current Assets | 3 Months Ended |
Jun. 30, 2020 | |
Prepaid Expense and Other Assets, Current [Abstract] | |
OTHER CURRENT ASSETS | Note 6 – OTHER CURRENT ASSETS Other current assets consisted of the following: June 30, March 31, Rental deposits (1) $ 1,558,965 $ 1,364,975 Prepaid and other current assets 276,962 163,565 Total $ 1,835,927 $ 1,528,540 (1) The balance as of June 30, 2020 and March 31, 2020 includes short-term refundable rental security deposits. |
Property and Equipment
Property and Equipment | 3 Months Ended |
Jun. 30, 2020 | |
Property, Plant and Equipment [Abstract] | |
PROPERTY AND EQUIPMENT | Note 7 – PROPERTY AND EQUIPMENT Property and equipment consisted of the following: June 30, March 31, Building $ 5,898,768 $ 5,880,627 Leasehold improvements 9,397,190 9,209,136 Farmland development cost 1,691,632 1,686,430 Office equipment and furniture 5,587,888 5,632,955 Motor vehicles 505,883 504,327 Total 23,081,361 22,913,475 Less: Accumulated depreciation (13,758,940 ) (13,059,852 ) Impairment* (2,226,731 ) (2,219,883 ) Property and equipment, net $ 7,095,690 $ 7,633,740 * The variance of impairment from March 31, 2020 to June 30, 2020 is solely caused by exchange rate variance. Depreciation expenses for property and equipment totaled $695,151 and $441,559 for the three months ended June 30, 2020 and 2019, respectively. There were no fixed assets impaired in the three months ended June 30, 2020 and June 30, 2019. |
Long-Term Investment
Long-Term Investment | 3 Months Ended |
Jun. 30, 2020 | |
Debt Disclosure [Abstract] | |
LONG-TERM INVESTMENT | Note 8 – LONG-TERM INVESTMENT Long-term investment consists of the following: June 30, March 31, Kahamadi Bio (1) $ 3,214 * $ 6,217 * Zhetong Medical (2) 3,960,544 2,538,234 Advance to suppliers, net $ 3,963,758 $ 2,544,451 (1) It represents 49% investment in Kahamadi Bio. The investment is recorded using the equity method. Kahamadi Bio suffered loss of $3,015 the three months ended June 30, 2020. (2) It represents 39% investment in Zhejiang Zhetong Medical Co., Ltd. Zhetong Medical was established in March 2020 to target potential acquisitions or cooperate with local pharmacies. By attracting more funds from local investors, the Company expects to continue growing its local network in the future. |
Advances to Suppliers
Advances to Suppliers | 3 Months Ended |
Jun. 30, 2020 | |
Advances to Suppliers [Abstract] | |
ADVANCES TO SUPPLIERS | Note 9 – ADVANCES TO SUPPLIERS Advances to suppliers consist of deposits, with or advances to, outside vendors for future inventory purchases. Most of the Company's suppliers require a certain amount of money to be deposited with them as a guarantee that the Company will receive its purchase on a timely basis. This amount is refundable and bears no interest. As of June 30, 2020 and March 31, 2020, advance to suppliers consist of the following: June 30, March 31, Advance to suppliers $ 3,160,046 $ 2,198,863 Less: allowance for unrefundable advances (922,326 ) (1,024,063 ) Advance to suppliers, net $ 2,237,720 $ 1,174,800 For the three months ended June 30, 2020 and 2019, none of the advances to suppliers were written off against previous allowance for unrefundable advances, respectively. |
Inventory
Inventory | 3 Months Ended |
Jun. 30, 2020 | |
Inventory Disclosure [Abstract] | |
INVENTORY | Note 10 – INVENTORY Inventory consisted of finished goods, valued at $11,141,411 and $12,247,004 as of June 30, 2020 and March 31, 2020, respectively. The Company constantly monitors its potential obsolete products and is allowed to return products close to their expiration dates to its suppliers. Any loss on damaged items is immaterial and will be recognized immediately. As a result, no reserves were made for inventory as of June 30, 2020 and March 31, 2020. |
Farmland Assets
Farmland Assets | 3 Months Ended |
Jun. 30, 2020 | |
Farmland Assets [Abstract] | |
FARMLAND ASSETS | Note 11 – FARMLAND ASSETS Farmland assets consist of ginkgo trees planted in 2012 and expected to be harvested and sold in several years. As of June 30, 2020 and March 31, 2020, farmland assets are valued as follows: June 30, March 31, 2020 2020 Farmland assets $ 2,191,944 $ 2,177,606 Less: Impairment* (1,439,687 ) (1,435,259 ) Farmland assets, net $ 752,257 $ 742,347 * As of March 31, 2018, the book value of the Ginkgo trees planted in Qianhong Agriculture's farmland, including their cultivation cost and land lease amortization expense, was approximately $2,416,839. Based on an independent appraisal report, the value of the Ginkgo trees was approximately $796,286 as of March 31, 2018. As a result, the Company recorded an agricultural inventory impairment of $1,620,553 as of March 31, 2018. The difference between the recorded impairment loss and impairment balance in the above is primarily due to the exchange rate variance over years. There are no leasehold impairment expense in the three months ended June 30, 2020 and 2019. |
Long Term Refundable Deposits,
Long Term Refundable Deposits, Landlords | 3 Months Ended |
Jun. 30, 2020 | |
Long Term Deposits, Landlords [Abstract] | |
LONG TERM REFUNDABLE DEPOSITS, LANDLORDS | Note 12 – LONG TERM REFUNDABLE DEPOSITS, LANDLORDS As of June 30, 2020 and March 31, 2020, long term deposits amounted to $1,447,547 and $1,456,384, respectively. Long term deposits are money deposited with, or advanced to, landlords for the purpose of securing retail store leases that the Company does not anticipate being returned within the next twelve months. Most of the Company's landlords require a minimum payment of nine months' rent, paid up front, plus additional deposits. |
Other Noncurrent Assets
Other Noncurrent Assets | 3 Months Ended |
Jun. 30, 2020 | |
Other Assets, Noncurrent Disclosure [Abstract] | |
OTHER NONCURRENT ASSETS | Note 13 – OTHER NONCURRENT ASSETS Other noncurrent assets consisted of the following: June 30, March 31, Forest land use rights* $ 985,156 $ 994,558 Others 64,028 52,205 Total $ 1,049,184 $ 1,046,763 * The prepayment for lease of forest land use rights is a payment made to a local government in connection with entering into an operating land lease agreement. The land is currently used to cultivate Ginkgo trees. The forest rights certificate from the local village extends the life of the lease to January 31, 2060. The amortization of the prepayment for the lease of forest land use right was approximately $12,441 and $6,885 for the three months ended June 30, 2020 and 2019, respectively. The Company's amortizations of the prepayment for lease of land use right for the next five years and thereafter are as follows: For the year ending June 30, Amount 2021 $ 26,515 2022 26,515 2023 26,515 2024 26,515 2025 26,515 Thereafter 852,581 |
Leases
Leases | 3 Months Ended |
Jun. 30, 2020 | |
Leases [Abstract] | |
LEASES | Note 14 – LEASES The Company leases most of its retail stores and corporate offices under operating leases, typically with initial terms of 3 to 10 years. Usually within one to three months prior to the expiration date of a lease, the Company is required to notify the lessor and has a priority to continue renting the lease property if a lessor intends to lease property. The lease itself does not have restriction or covenants. If both parties agree to continue, a new lease contract with new lease terms has to been signed by both parties. Usually the rent may increase year by year based on the lease contract. Sublease is typically not allowed. Any damage, if made by the lessee, to the property and equipment within the property has to been fixed or reimbursed by the lessee. The Company does not have any leases entered into but which have not yet commenced. The net lease cost for the three months ended June 30, 2020 is $1,671,118. The Company does not have finance lease according to the definition of ASU 2016-02, Leases Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows paid for operating leases $ 1,671,118 Right-of-use assets obtained in exchange for lease obligations: Operating leases - Supplemental balance sheet information related to leases as of June 30, 2020 is as follows: Operating leases: Operating lease right-of-use assets $ 19,351,247 Current portion of operating lease liabilities $ 466,213 Long-term operating lease liabilities 16,917,159 Total operating lease liabilities $ 17,383,372 Weighted average remaining lease term Operating leases 3.2 Weighted average discount rate Operating leases 4.19 % The following table summarizes the maturity of lease liabilities under operating leases as of June 30, 2020: Operating For the year ending June 30, Leases 2021 $ 485,355 2022 6,345,189 2023 4,510,762 2024 3,277,971 2025 1,995,568 Thereafter 2,575,035 Total lease payments 19,189,880 Less: imputed interest (1,806,508 ) Total lease liabilities $ 17,383,372 |
Intangible Assets
Intangible Assets | 3 Months Ended |
Jun. 30, 2020 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
INTANGIBLE ASSETS | Note 15 – INTANGIBLE ASSETS Net intangible assets consisted of the following at: June 30, March 31, License (1) $ 2,246,880 $ 2,220,512 Software (2) 1,086,366 1,083,024 Land use rights (3) 1,379,337 1,375,095 Total intangible assets 4,712,583 4,678,631 Less: accumulated amortization (735,234 ) (667,633 ) Less: impairment (4) (618,942 ) (617,038 ) Intangible assets, net $ 3,358,407 $ 3,393,960 Amortization expense of intangibles amounted to $65,389 and $58,466 for the three months ended June 30, 2020 and 2019, respectively. (1) This represents the fair value of the licenses of insurance applicable drugstores acquired from a variety of drugstores such as Sanhao Pharmacy and several local stores. The licenses allow patients to pay by using insurance cards at stores. The stores are reimbursed from the Human Resource and Social Security Department of Hangzhou City. In 2014, the Company acquired Sanhao Pharmacy, a drugstore chain. In September 2017, the Company acquired several new stores for the purpose of the Municipal Social Medical Reimbursement Qualification Certificates. On January 9, 2020, the Company acquired a local drugstore chain. The acquired drugstores ceased their stores' business and liquidate all of the stores' accounts after Jiuzhou Pharmacy acquired them. In March 2020, the drugstore chain has dissolved and its certificates were transferred to new stores opened at the same time. (2) These balances primarily include the SAP ERP system, the Internet Clinic Diagnosis Terminal system and the Chronic Disease Management system. In 2017, we have installed a leading ERP system, SAP from Germany. SAP is a well-known management system used by many fortune 500 companies. It is being amortized over three years since its installation. In 2020, we have installed an internet Clinic Diagnosis System used to strengthen our ability to perform online diagnosis which may increase more customer spending and a Chronic Disease Management System used to better manage and monitor our members' health. As of June 30, 2020, the SAP system has a net value of $135,698 (RMB 959,352), the internet Clinic Diagnosis System has a net value of approximately $380,313 (RMB 2,688,709), the Chronic Disease Management System has a net value of approximately $16,462 (RMB 116,379) . (3) In July 2013, the Company purchased the land use rights of a plot of land in Lin'an, Hangzhou, intended for the establishment of an herb processing plant in the future. However, as the Company's farming business in Lin'an has not grown, the Company does not expect completion of the plant in the near future. (4) In the year ended March 31, 2020, the company evaluated the licenses of insurance applicable drugstores acquired in the past based on the discounted positive cash value. Due to the stricter government insurance policy in fiscal year 2021, the value of these licenses has declined. As a result, the company recorded an impairment. There are no impairment expense in the three months ended June 30, 2020 and 2019. |
Notes Payable
Notes Payable | 3 Months Ended |
Jun. 30, 2020 | |
Notes Payable [Abstract] | |
NOTES PAYABLE | Note 16 – NOTES PAYABLE The Company has credit facilities with Hangzhou United Bank ("HUB") that provided working capital in the form of the following bank acceptance notes at June 30, 2020 and March 31, 2020: Origination Maturity June 30, March 31, Beneficiary Endorser date date 2020 2020 Jiuzhou Pharmacy(1) HUB 10/09/19 04/09/20 - 3,478,259 Jiuzhou Pharmacy(1) HUB 11/06/19 05/06/20 - 164,582 Jiuzhou Pharmacy(1) HUB 12/05/19 06/05/20 - 3,106,474 Jiuzhou Pharmacy(1) HUB 12/31/19 06/30/20 - 2,289,308 Jiuzhou Pharmacy(1) HUB 01/06/20 07/06/20 129,856 129,457 Jiuzhou Pharmacy(1) HUB 02/19/20 08/19/20 5,120,844 5,105,096 Jiuzhou Pharmacy(1) HUB 03/10/20 09/10/20 5,341,297 5,324,871 Jiuxin Medicine(1) HUB 12/26/19 06/26/20 - 1,371,992 Jiuxin Medicine(1) HUB 12/31/19 06/30/20 3,943,776 Jiuxin Medicine(1) HUB 03/31/20 09/30/20 1,697,376 1,692,156 Jiuzhou Pharmacy(1) HUB 04/10/20 10/10/20 2,969,129 Jiuzhou Pharmacy(1) HUB 04/29/20 10/29/20 546,874 Jiuzhou Pharmacy(1) HUB 05/09/20 11/09/20 3,803,552 - Jiuzhou Pharmacy(1) HUB 06/24/20 12/24/20 1,405,995 - Jiuzhou Pharmacy(1) HUB 06/30/20 12/30/20 891,122 - Jiuxin Medicine(1) HUB 06/30/20 12/30/20 4,809,329 - Total $ 26,715,374 $ 26,605,971 (1) As of June 30, 2020, the Company had $26,715,374 (RMB 188,870,639) of notes payable from HUB. The Company is required to hold restricted cash in the amount of $14,913,825 (RMB 105,684,113) with HUB as collateral against these bank notes. Included in the restricted cash is a total of $8,770,422 three-year deposit (RMB 62,150,000) deposited into HUB as a collateral for current and future notes payable from HUB. As of March 31, 2020, the Company had $26,605,971 (RMB 188,677,437) of notes payable from HUB. The Company is required to hold restricted cash in the amount of $14,596,179 (RMB 103,509,456) with HUB as collateral against these bank notes. Included in the restricted cash is a total of $8,763,958 three-year deposit (RMB 62,150,000) deposited into HUB as a collateral for current and future notes payable from HUB. As of June 30, 2020, the Company had a credit line of approximately $12.55 million in the aggregate from HUB. By putting up a three-year deposit of $8.77 million and the additional short-term deposits of $6.14 million deposited in the banks, the total credit line was $27.46 million. As of June 30, 2020, the Company had approximately $26.72 million of bank notes payable and approximately $0.74 million bank credit line was still available for further borrowing. The bank notes are secured by three shops of Jiuzhou Pharmacy and guaranteed by the Company's major shareholders. |
Loan Payable
Loan Payable | 3 Months Ended |
Jun. 30, 2020 | |
Loan Payable [Abstract] | |
LOAN PAYABLE | Note 17 – LOAN PAYABLE On August 2, 2019 and December 11, 2019, the Company borrowed $717,810 and $6,460,290 from Haihui Commercial, respectively. After deducting processing fee and deposits which are refundable at the end of loan period, the Company received $617,317 and $5,878,864 respectively. The Company is required to pledge accounts receivable of three drugstores to Haihui Commercial. As of June 30, 2020, the remaining loan balance is $5,851,778. The Company is scheduled to make monthly repayments, among which $2,300,271 is due within a year. The Company has an option to pay off the debts earlier than the repayment schedule upon approval from Haihui Commercial. |
Taxes
Taxes | 3 Months Ended |
Jun. 30, 2020 | |
Income Tax Disclosure [Abstract] | |
TAXES | Note 18 – TAXES Income tax Income tax expense includes a provision for federal, state and foreign taxes based on the annual estimated effective tax rate applicable to the Company and its subsidiaries, adjusted for items which are considered discrete to the period. The effective tax rates on income before income taxes for the three months ended June 30, 2020 was (17.4)%. The (17.4) % rate adjustments for the three months ended June 30, 2020 represent expenses that primarily include stock option expenses and legal, accounting and other expenses incurred by the Company that are not deductible for PRC income tax. The effective tax rate is based on forecasted annual results and these amounts may fluctuate significantly through the rest of the year as a result of the unpredictable impact of COVID-19 on its operating activities. The effective tax rate on income before income taxes for the three months ended June 30, 2019 was (0.4)%. The (0.4)% rate adjustments for the three months ended June 30, 2019 represent expenses that primarily include stock option expenses and legal, accounting and other expenses incurred by the Company that are not deductible for PRC income tax. The Company has recorded $0 unrecognized benefit as of June 30, 2020. On the information currently available, the Company does not anticipate a significant increase or decrease to its unrecognized benefit within the next 12 months. |
Postretirement Benefits
Postretirement Benefits | 3 Months Ended |
Jun. 30, 2020 | |
Retirement Benefits [Abstract] | |
POSTRETIREMENT BENEFITS | Note 19 – POSTRETIREMENT BENEFITS Regulations in the PRC require the Company to contribute to a defined contribution retirement plan for all permanent employees. The contribution for each employee is based on a percentage of the employee's current compensation as required by the local government. The Company contributed $204,538 and $341,024 in employment benefits and pension for the three months ended June 30, 2020 and 2019, respectively. |
Related Party Transactions and
Related Party Transactions and Arrangements | 3 Months Ended |
Jun. 30, 2020 | |
Related Party Transactions [Abstract] | |
RELATED PARTY TRANSACTIONS AND ARRANGEMENTS | Note 20 – RELATED PARTY TRANSACTIONS AND ARRANGEMENTS Amounts payable to related parties are summarized as follows: June 30, March 31, Due to a director and CEO (1) 491,300 490,218 (1) Due to foreign exchange restrictions, the Company's director and CEO, Mr. Lei Liu personally lent U.S. dollars to the Company to facilitate its payments of expenses in the United States. The Company leases from Mr. Lei Liu a retail space; the lease expires in September 2020. Rent expenses totaled $6,532 and $6,785 for the three months ended June 30, 2020 and 2019, respectively. The amounts owed under the lease for the three months ended June 30, 2020 and 2019 were not paid to Mr. Liu as of June 30, 2020. On April 28, 2018, 10% of Jiuxin Medicine was sold to Hangzhou Kangzhou Biotech Co. Ltd. for a total proceeds of approximately $75,643 (RMB507,760). Mr. Lei Liu owns 51% of Hangzhou Kangzhou Biotech Co. Ltd. |
Warrants
Warrants | 3 Months Ended |
Jun. 30, 2020 | |
Warrants [Abstract] | |
WARRANTS | Note 21 – WARRANTS In connection with the registered direct offering closed on July 19, 2015, the Company issued to an investor a warrant to purchase up to 600,000 shares of common stock at an exercise price of $3.10 per share. The warrant became exercisable on January 19, 2016 and will expire on January 18, 2021. In connection with the offering, the Company also issued a warrant to its placement agent of this offering, pursuant to which the agent may purchase up to 6% of the aggregate number of shares of common stock sold in the offering, i.e. 72,000 shares. Such warrant has the same terms as the warrant issued to investor in the offering. On June 1, 2020, the investor exercised 25,000 warrants at the price of $3.10 per share in cash. As of June 30, 2020, 647,000 warrants had not been exercised. The fair value of the warrants issued to purchase 647,000 and 672,000 shares as of June 30, 2020 and March 31, 2020, as described above was estimated by using the binominal pricing model with the following assumptions: Common Stock Common Stock June 30, March 31, Stock price $ 1.44 $ 1.77 Exercise price $ 3.10 $ 3.10 Annual dividend yield - % - % Expected term (years) 0.56 0.81 Risk-free interest rate 0.18 % 0.71 % Expected volatility 98.86 % 62.08 % Upon evaluation, the warrants meet the definition of a derivative under FASB ASC 815, as the Company cannot avoid a net cash settlement under certain circumstances. Accordingly, the fair value of the warrants was classified as a liability of $64,090 as of March 31, 2020. For the three months ended June 30, 2020 and June 30, 2019, the Company recognized a loss of $4,890 and a gain of $403,555 for the investor warrant and placement agent warrant, from the change in fair value of the warrant liability. As a result, the warrant liability is carried on the consolidated balance sheets at the fair value of $68,980 for the investor warrant and placement agent warrant, collectively, as of June 30, 2020. |
Employee Deposits
Employee Deposits | 3 Months Ended |
Jun. 30, 2020 | |
Financial Liability [Abstract] | |
Employee Deposits | Note 22 – EMPLOYEE DEPOSITS To encourage operating team, which consists of doctors and nurses, to devote their efforts to run clinics, Linjia Medical allows them to put deposits in the clinic where doctors and nurses work, and take shares in any profit of the clinic. The principal amounts of these deposits are refundable in the event the doctors and nurses leave the clinic. In order to properly reflect Linjia Medical's liabilities, the Company reclassified the deposit of $14,145 (RMB100,000) and $70,507 (RMB500,000) as financial liability as of June 30, 2020 and March 31, 2020. |
Stockholder's Equity
Stockholder's Equity | 3 Months Ended |
Jun. 30, 2020 | |
Stockholders' Equity Note [Abstract] | |
STOCKHOLDER'S EQUITY | Note 23 – STOCKHOLDER'S EQUITY Common stock On April 15, 2019, the Company closed a registered direct offering of 4,000,008 shares of common stock at $2.50 per share with gross proceeds of $10,000,020 from our effective shelf registration statement. On June 1, 2020, an investor exercised 25,000 warrants at the price of $3.10 per share in cash. The Company issued 25,000 shares of common stocks. On June 3, 2020, the Company closed a registered direct offering of 5,000,004 shares of common stock at $2.00 per share with gross proceeds of $10,000,008 from its effective shelf registration statement. Stock warrants Concurrent with the registered direct offering of common stock that closed on April 15, 2019, the Company issued to several investors in a private placement warrants to purchase up to 3,000,006 shares of common stock. In connection with the offering, the Company also issued a warrant to its placement agent of this offering, pursuant to which the agent may purchase up to 6% of the aggregate number of shares of common stock sold in the offering, i.e. 240,000 shares at an exercise price of $3.125 per share. The warrant became exercisable on October 11, 2019 and will expire on April 11, 2024. Concurrent with the registered direct offering of common stock that closed on June 3, 2020, the Company issued to several investors in a private placement warrants to purchase up to 3,750,003 shares of common stock. In connection with the offering, the Company also issued a warrant to its placement agent of this offering, pursuant to which the agent may purchase up to 6.5% of the aggregate number of shares of common stock sold in the offering, i.e. 300,000 shares at an exercise price of $2.57 per share. The warrant becomes exercisable on December 2, 2020 and will expire on June 2, 2025. Upon evaluation, both the warrants issued in April 2019 and June 2020 meet the definition of an equity transaction under FASBASC 815. Accordingly, the fair value of the warrants is recorded as a part of additional paid-in capital. Stock-based compensation The Company accounts for share-based payment awards granted to employees and directors by recording compensation expense based on estimated fair values. The Company estimates the fair value of share-based payment awards on the date of grant. The value of the portion of the award that is ultimately expected to vest is recognized as an expense over the requisite service periods in the Company's consolidated statements of operations. Share-based awards are attributed to expenses using the straight-line method over the vesting period. The Company determines the value of each option award that contains a market condition using a Monte Carlo Simulation valuation model, while all other option awards are valued using the Black-Scholes valuation model as permitted under FASB ASC 718 "Compensation - Stock Compensation." The assumptions used in calculating the fair value of share-based payment awards represent the Company's best estimates. The Company's estimates of the fair values of stock options granted and the resulting amounts of share-based compensation recognized may be impacted by certain variables including stock price volatility, employee stock option exercise behaviors, additional stock option modifications, estimates of forfeitures, and the related income tax impact. Stock option On November 18, 2014, the Company granted a total of 967,000 shares of stock options under the Plan to a group of a total of 46 grantees including directors, officers and employees. The exercise price of the stock option is $2.50. The option vests on November 18, 2017, provided that the grantees are still employed by the Company on such a date. The options will be exercisable for five years from the vesting date, or November 18, 2017 until November 17, 2022. For the three months ended June 30, 2020 and 2019, none was recorded as compensation expense. As of June 30, 2020, all compensation costs related to stock option compensation arrangements granted have been recognized. Statutory reserves Statutory reserves represent restricted retained earnings. Based on their legal formation, the Company is required to set aside 10% of its net income as reported in their statutory accounts on an annual basis to the Statutory Surplus Reserve Fund (the "Reserve Fund"). Once the total amount set aside in the Reserve Fund reaches 50% of the entity's registered capital, further appropriations become discretionary. The Reserve Fund can be used to increase the entity's registered capital upon approval by relevant government authorities or eliminate its future losses under PRC GAAP upon a resolution by its board of directors. The Reserve Fund is not distributable to shareholders, as cash dividends or otherwise, except in the event of liquidation. Appropriations to the Reserve Fund are accounted for as a transfer from unrestricted earnings to statutory reserves. During the three months ended June 30, 2020 and 2019, the Company did not make appropriations to statutory reserves. There are no legal requirements in the PRC to fund the Reserve Fund by transfer of cash to any restricted accounts, and the Company does not do so. |
Loss Per Share
Loss Per Share | 3 Months Ended |
Jun. 30, 2020 | |
Loss Per Share [Abstract] | |
LOSS PER SHARE | Note 24 – LOSS PER SHARE The Company reports earnings per share in accordance with the provisions of the FASB's related accounting standard. This standard requires presentation of basic and diluted earnings per share in conjunction with the disclosure of the methodology used in computing such earnings per share. Basic earnings per share excludes dilution, but includes vested restricted stocks and is computed by dividing income available to common stockholders by the weighted average common shares outstanding during the period. Diluted earnings per share takes into account the potential dilution that could occur if securities or other contracts to issue common stock were exercised and converted into common stock. The following is a reconciliation of the basic and diluted (loss) earnings per share computation: The three months ended 2020 2019 Net loss attributable to controlling interest $ (231,509 ) $ (2,134,951 ) Weighted average shares used in basic computation 34,428,271 32,453,269 Diluted effect of stock options and warrants - - Weighted average shares used in diluted computation 34,428,271 32,453,269 Loss per share – Basic: - - Net loss attributable to controlling interest $ (0.01 ) $ (0.07 ) Loss per share – Diluted: Net loss attributable to controlling interest $ (0.01 ) $ (0.07 ) For the three months ended June 30, 2020, 967,000 shares underlying employee stock options and 575,000 shares underlying outstanding purchase options to an investor, and 72,000 shares underlying outstanding purchase option to an investment placement agent were excluded from the calculation of diluted loss per share as the options were anti-dilutive. |
Segments
Segments | 3 Months Ended |
Jun. 30, 2020 | |
Segment Reporting [Abstract] | |
SEGMENTS | Note 25 – SEGMENTS The Company operates within four main reportable segments: retail drugstores, online pharmacy, drug wholesale and herb farming. The retail drugstores segment sells prescription and over-the-counter ("OTC") medicines, TCM, dietary supplements, medical devices, and sundry items to retail customers. The online pharmacy sells OTC drugs, dietary supplements, medical devices and sundry items to customers through several third-party platforms such as Alibaba's Tmall, JD.com and Amazon.com, and the Company's own platform all over China. The drug wholesale segment includes supplying the Company's own retail drugstores with prescription and OTC medicines, TCM, dietary supplement, medical devices and sundry items (which sales have been eliminated as intercompany transactions), and also selling them to other drug vendors and hospitals. The Company's herb farming segment cultivates selected herbs for sales to other drug vendors. The Company is also involved in online sales and clinic services that do not meet the quantitative thresholds for reportable segments and are included in the retail drugstores segment. The segments' accounting policies are the same as those described in the summary of significant accounting policies. The Company evaluates performance based on profit or loss from operations before interest and income taxes not including nonrecurring gains and losses. The Company's reportable business segments are strategic business units that offer different products and services. Each segment is managed separately because they require different operations and markets to distinct classes of customers. The following table presents summarized information by segment of the continuing operations for the three months ended June 30, 2020. Retail drugstores Online Pharmacy Drug wholesale Herb Total Revenue $ 18,810,474 $ 4,912,834 7,331,004 - 31,054,312 Cost of goods 12,402,182 4,228,411 6,443,500 - 23,074,093 Gross profit $ 6,408,292 $ 684,423 887,504 - 7,980,219 Selling expenses 4,977,047 704,876 590,484 - 6,272,407 General and administrative expenses 1,128,083 59,011 933,072 - 2,120,166 Loss from operations $ 303,162 $ (79,464 ) (636,052 ) - (412,354 ) Depreciation and amortization $ 750,498 $ - 10,042 - 760,540 Total capital expenditures $ 169,807 $ - - 169,807 The following table presents summarized information by segment of the continuing operations for the three months ended June 30, 2019. Retail drugstores Online Pharmacy Drug wholesale Herb Total Revenue $ 16,734,988 $ 2,443,605 6,102,191 - 25,280,784 Cost of goods 11,682,721 2,096,850 5,439,775 - 19,219,346 Gross profit $ 5,052,267 $ 346,755 662,416 - 6,061,438 Selling expenses 4,835,666 473,380 659,505 - 5,968,551 General and administrative expenses 1,733,704 55,123 1,062,785 - 2,851,612 Loss from operations $ (1,517,103 ) $ (181,748 ) (1,059,874 ) - (2,758,725 ) Depreciation and amortization $ 504,463 $ - 8,486 - 512,949 Total capital expenditures $ 753,173 $ - - 753,173 The Company does not have long-lived assets located outside the PRC. In accordance with the enterprise-wide disclosure requirements of FASB's accounting standard. The Company's net revenue from external customers through its retail drugstores by main product category for the three months ended June 30, 2020 and 2019 were as follows: For the three months ended June 30, 2020 2019 Prescription drugs $ 7,406,774 $ 5,695,286 OTC drugs 6,818,484 7,240,228 Nutritional supplements 1,347,769 1,231,133 TCM 949,012 1,104,050 Sundry products 422,551 298,198 Medical devices 1,865,884 1,166,093 Total $ 18,810,474 $ 16,734,988 The Company's net revenue from external customers through online pharmacy by main product category is as follows: For the three months ended June 30, 2020 2019 Prescription drugs $ 1,869,643 $ - OTC drugs 1,322,811 1,024,602 Nutritional supplements 221,031 107,194 TCM 23,199 13,681 Sundry products 546,720 438,736 Medical devices 929,430 859,392 Total $ 4,912,834 $ 2,443,605 The Company's net revenue from external customers through wholesale by main product category is as follows: For the three months ended June 30, 2020 2019 Prescription drugs $ 5,966,148 $ 4,880,491 OTC drugs 915,146 1,074,261 Nutritional supplements 59,841 21,691 TCM 28,967 98,828 Sundry products 2,597 5,682 Medical devices 358,305 21,238 Total $ 7,331,004 $ 6,102,191 |
Subsequent Events
Subsequent Events | 3 Months Ended |
Jun. 30, 2020 | |
Subsequent Events [Abstract] | |
SUBSEQUENT EVENTS | Note 26 – Subsequent Events Management of the Company has evaluated subsequent events through the date of the report, and there was no material subsequent event requiring adjustments to the financial statements or disclosure. |
Summary of Significant Accoun_2
Summary of Significant Accounting Policies (Policies) | 3 Months Ended |
Jun. 30, 2020 | |
Accounting Policies [Abstract] | |
Basis of presentation and consolidation | Basis of presentation and consolidation The accompanying condensed consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”). The consolidated financial statements include the financial statements of the Company, its wholly-owned subsidiaries and VIEs. All significant inter-company transactions and balances between the Company, its subsidiaries and VIEs are eliminated upon consolidation. |
Consolidation of variable interest entities | Consolidation of variable interest entities In accordance with accounting standards regarding consolidation of variable interest entities, VIEs are generally entities that lack sufficient equity to finance their activities without additional financial support from other parties or whose equity holders lack adequate decision making ability. All VIEs with which the Company is involved must be evaluated to determine the primary beneficiary of the risks and rewards of the VIE. The primary beneficiary is required to consolidate the VIE for financial reporting purposes. The Company has concluded, based on the contractual arrangements, that Jiuzhou Pharmacy (including its subsidiaries and controlled entities), Jiuzhou Clinic and Jiuzhou Service are each a VIE and that the Company’s wholly-owned subsidiary, Jiuxin Management, absorbs a majority of the risk of loss from the activities of these companies, thereby enabling the Company, through Jiuxin Management, to receive a majority of their respective expected residual returns. Control and common control are defined under the accounting standards as “an individual, enterprise, or immediate family members who hold more than 50 percent of the voting ownership interest of each entity.” Because the Owners collectively own 100% of Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service, and have agreed to vote their interests in concert since the establishment of each of these three companies as memorialized in the voting rights agreement, the Company believes that the Owners collectively have control and common control of the three companies. Accordingly, the Company believes that Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service were constructively held under common control by Jiuxin Management as of the time the Contractual Agreements were entered into, establishing Jiuxin Management as their primary beneficiary. Jiuxin Management, in turn, is owned by Renovation, which is owned by the Company. |
Risks and Uncertainties | Risks and Uncertainties The operations of the Company are located in the PRC. Accordingly, the Company’s business, financial condition, and results of operations may be influenced by political, economic, and legal environments in the PRC, as well as by the general state of the PRC economy. The Company’s operations in the PRC are subject to special considerations and significant risks not typically associated with companies in North America and Western Europe. These include risks associated with, among others, the political, economic and legal environment and foreign currency exchange. The Company’s results may be adversely affected by changes in the political, regulatory and social conditions in the PRC. Although the Company has not experienced losses from these situations and believes that it is in compliance with existing laws and regulations including its organization and structure disclosed in Note 1, this may not be indicative of future results. The Company has significant cash deposits with suppliers in order to obtain and maintain inventory. The Company’s ability to obtain products and maintain inventory at existing and new locations is dependent upon its ability to post and maintain significant cash deposits with its suppliers. In the PRC, many vendors are unwilling to extend credit terms for product sales that require cash deposits to be made. The Company does not generally receive interest on any of its supplier deposits, and such deposits are subject to loss as a result of the creditworthiness or bankruptcy of the party who holds such funds, as well as the risk from illegal acts such as conversion, fraud, theft or dishonesty associated with the third party. If these circumstances were to arise, the Company would find it difficult or impossible, due to the unpredictability of legal proceedings in China, to recover all or a portion of the amount on deposit with its suppliers. Members of the current management team own controlling interests in the Company and are also the Owners of the VIEs in the PRC. The Company only controls the VIEs through contractual arrangements which obligate it to absorb the risk of loss and to receive the residual expected returns. As such, the controlling shareholders of the Company and the VIEs could cancel these agreements or permit them to expire at the end of the agreement terms, as a result of which the Company would not retain control of the VIEs. |
Use of estimates | Use of estimates The preparation of consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. The significant estimates made in the preparation of the accompanying consolidated financial statements relate to the assessment of the carrying values of accounts receivable, advances to suppliers and related allowance for doubtful accounts, useful lives of property and equipment, inventory reserve and fair value of its purchase option derivative liability. Because of the use of estimates inherent in the financial reporting process, actual results could materially differ from those estimates. |
Fair value measurements | Fair value measurements The Company establishes a three-level valuation hierarchy of valuation techniques based on observable and unobservable inputs, which may be used to measure fair value and include the following: Level 1 – Quoted prices in active markets for identical assets or liabilities. Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Classification within the hierarchy is determined based on the lowest level of input that is significant to the fair value measurement. The Company’s financial assets and liabilities, which include financial instruments as defined by FASB ASC 820, include cash and cash equivalents, restricted cash, financial assets available for sales, accounts receivable, notes receivables, other receivable, accounts payable, notes payable, other payable, long-term debt and derivatives. The carrying amounts of cash and cash equivalents, restricted cash, accounts receivable, notes receivables, and accounts payable are a reasonable approximation of fair value due to the short maturities of these instruments (Level 1). The carrying amount of notes payable approximates fair value based on borrowing rates of similar bank loan currently available to the Company (Level 2) (See Note 16). The carrying amount of Long-term loan payable approximates fair value based on borrowing rates of similar bank loan currently available to the Company (Level 2) (See Note 17).The carrying amount of the Company’s derivative instruments is recorded at fair value and is determined based on observable inputs that are corroborated by market data (Level 2) (See Note 21). The carrying amount of the financial assets available for sale is recorded at fair value and is determined based on unobservable inputs (Level 3) (See Note 4). The carrying amount of the employee deposits is recorded at fair value and is determined based on unobservable inputs (Level 3) (See Note 22). Active Market Observable Unobservable Total Cash, cash equivalents and restricted cash $ 33,572,328 - - 33,572,328 Financial assets available for sale - - 157,644 157,644 Account receivable 8,984,595 - - 8,984,595 Notes receivable 28,290 - - 28,290 Other receivable 5,599,565 - - 5,599,565 Accounts payable 16,107,594 - - 16,107,594 Notes payable - 26,715,374 - 26,715,374 Other payable 2,176,992 - - 2,176,992 Long-term loan payable - 5,851,778 - 5,851,778 Employee Deposits - - 14,145 14,145 Warrants liability - 68,980 - 68,980 Total $ 66,469,364 32,636,132 171,789 99,277,285 |
Revenue recognition | Revenue recognition Effective March 31, 2018, the Company began recognizing revenue under Accounting Standards Codification ("ASC") Topic 606, Revenue from Contracts with Customers ("ASC 606"), using the modified retrospective transition method. The impact of adopting the new revenue standard was not material to the Company's consolidated financial statements. The core principle of this new revenue standard is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. The following five steps are applied to achieve that core principle: ● Step 1: Identify the contract with the customer ● Step 2: Identify the performance obligations in the contract ● Step 3: Determine the transaction price ● Step 4: Allocate the transaction price to the performance obligations in the contract ● Step 5: Recognize revenue when the company satisfies a performance obligation In order to identify the performance obligations in a contract with a customer, a company must assess the promised goods or services in the contract and identify each promised good or service that is distinct. A performance obligation meets ASC 606's definition of a "distinct" good or service (or bundle of goods or services) if both of the following criteria are met: ● The customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer (i.e., the good or service is capable of being distinct). ● The entity's promise to transfer the good or service to the customer is separately identifiable from other promises in the contract (i.e., the promise to transfer the good or service is distinct within the context of the contract). If a good or service is not distinct, the good or service is combined with other promised goods or services until a bundle of goods or services is identified that is distinct. The transaction price is the amount of consideration to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer, excluding amounts collected on behalf of third parties (for example, some sales taxes). The consideration promised in a contract with a customer may include fixed amounts, variable amounts, or both. Variable consideration is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. The transaction price is allocated to each performance obligation on a relative standalone selling price basis. The transaction price allocated to each performance obligation is recognized when that performance obligation is satisfied, at a point in time or over time as appropriate. The Company's revenue is net of value added tax ("VAT") collected on behalf of the PRC tax authorities with respect to the sales of merchandise. VAT collected from customers, net of VAT paid for purchases, is recorded as a liability in the accompanying consolidated balance sheets until it is paid to the relevant PRC tax authorities. Certain contract liabilities primarily represent the Company's obligation to transfer additional goods or services to a customer for which the Company has received consideration, for example, membership points. The consideration received remains a contract liability until goods or services have been provided to the retail customer. The estimated amount based on accrued membership points was deducted from sales revenue. The following is a discussion of the Company's revenue recognition policies by segment under the new revenue recognition accounting standard: Pharmacy retail sales The physical pharmacies sell prescription drugs, over-the-counter ("OTC") drugs, traditional Chinese medicine, nutritional supplements, medical devices and sundry products. Revenue from sales of prescription medicine at drugstores is recognized when the prescription is filled and the customer picks up and pays for the prescription. Revenue from sales of other merchandise at drugstores is recognized at the point of sale, which is when a customer pays for and receives the merchandise. Usually the majority merchandise, such as prescription and OTC drugs, are not refundable after the customers leave the counter. Returns of other products, such as sundry products, are minimal. Sales of drugs reimbursed by the local government medical insurance agency and receivables from the agency are recognized when a customer pays for the drugs at a store. The Company based on historical experience, a reserve for potential losses from denial of reimbursement on certain unqualified drugs is made to the receivables from the government agency. Additionally, several onsite clinics adjacent to pharmacies provide limited medical services. Revenue from medical services is recognized after the service has been rendered to a customer. As revenue from medical services is minimal compared to pharmacy retail sales, it is included as part of the pharmacy retail sales. The Company deduct the membership rewards directly from the retail revenue, and present such amounts in net sales as opposed to the current reduction of operation expense classification. Membership rewards, usually membership points, are accumulated by customers based on their historical spending levels. The Company has determined that there is an additional performance obligation to those customers at the time of the initial transaction. The customers can then redeem these points against the prices of merchandises they purchase in the future. At the end of each period, unredeemed membership rewards are reflected as a contract liability. Online pharmacy sales The online pharmacy segment sells various health products except for prescription drugs. Revenue from online pharmacy sales is recognized when merchandise is shipped to customers. While most deliveries take one day, certain deliveries may take longer depending on a customer's location. Any loss caused in a shipment will be reimbursed by the Company's courier company. The Company's sales policy allows for the return of certain merchandises without reason within seven days after a customer's receipt of the applicable merchandise. Historically, sales returns seven days after merchandise receipts have been minimal. Wholesale Jiuxin Medicine purchases medicine in quantity and distributes products primarily to local pharmacies and medical products dealers. Revenue from sales of merchandise to non-retail customers is recognized when the merchandise is transferred to customers. Historically, sales returns have been minimal. Disaggregation of Revenue The following table disaggregates the Company's revenue by major source in each segment for the three months ended June 30, 2020 and 2019: For the three months ended June 30 2020 2019 Retail drugstores Prescription drugs $ 7,406,774 $ 5,695,286 OTC drugs 6,818,484 7,240,228 Nutritional supplements 1,347,769 1,231,133 TCM 949,012 1,104,050 Sundry products 422,551 298,198 Medical devices 1,865,884 1,166,093 Total retail revenue $ 18,810,474 $ 16,734,988 Online pharmacy Prescription drugs $ 1,869,643 $ - OTC drugs 1,322,811 1,024,602 Nutritional supplements 221,031 107,194 TCM 23,199 13,681 Sundry products 546,720 438,736 Medical devices 929,430 859,392 Total online revenue $ 4,912,834 $ 2,443,605 Drug wholesale Prescription drugs $ 5,966,148 $ 4,880,491 OTC drugs 915,146 1,074,261 Nutritional supplements 59,841 21,691 TCM 28,967 98,828 Sundry products 2,597 5,682 Medical devices 358,305 21,238 Total wholesale revenue $ 7,331,004 $ 6,102,191 Total revenue $ 31,054,312 $ 25,280,784 Contract Balances Contract liabilities primarily represent the Company's obligation to transfer additional goods or services to a customer for which the Company has received consideration, for example membership points and membership rewards. The consideration received remains a contract liability until goods or services have been provided to the retail customer. The following table provides information about receivables and contract liabilities from contracts with customers: June 30, March 31, Trade receivable(included in accounts receivable, net) $ 8,984,595 $ 9,770,656 Contract liabilities (included in accrued expenses) 1,112,508 1,106,982 |
Restricted cash | Restricted cash The Company's restricted cash consists of cash and long-term deposits in a bank as security for its notes payable. The Company has notes payable outstanding with the bank and is required to keep certain amounts on deposit that are subject to withdrawal restrictions. The notes payable are generally short term in nature due to their short maturity period of six to nine months; thus, restricted cash is classified as a current asset. The following represents a reconciliation of cash and cash equivalents in the Consolidated Condensed Balance Sheets to total cash, cash equivalents and restricted cash in the Consolidated Condensed Statements of Cash Flows as of June 30, 2020 and March 31, 2020: June 30, March 31, Cash and cash equivalents $ 18,477,212 $ 16,176,318 Restricted cash 15,095,116 14,806,288 Cash, cash equivalents and restricted cash $ 33,572,328 $ 30,982,606 |
Accounts receivable | Accounts receivable Accounts receivable represents the following: (1) amounts due from banks relating to retail sales that are paid or settled by the customers' debit or credit cards, (2) amounts due from government social security bureaus and commercial health insurance programs relating to retail sales of drugs, prescription medicine, and medical services that are paid or settled by the customers' medical insurance cards, (3) amounts due from non-bank third party payment instruments such as Alipay and certain e-commerce platforms and (4) amounts due from non-retail customers for sales of merchandise. Accounts receivable are recorded at net realizable value consisting of the carrying amount less an allowance for uncollectible accounts, as necessary. In the Company's retail business, accounts receivable mainly consist of reimbursements due from the government insurance bureaus and commercial health insurance programs and are usually collected within two or three months. The Company directly writes off delinquent account balances, which it determines to be uncollectible after confirming with the appropriate bureau or program each month. Additionally, the Company also makes estimated reserves on related outstanding accounts receivable based on historical trends. In the Company's online pharmacy business, accounts receivable primarily consist of amounts due from non-bank third party payment instruments such as Alipay and certain e-commerce platforms. To purchase pharmaceutical products from an e-commerce platforms such as Tmall, customers are required to submit payment to certain non-bank third party payment instruments, such as Alipay, which, in turn, reimburse the Company within seven days to a month. Except for customer returns of sold products, the receivables from these payments instruments are rarely uncollectible. In its wholesale business, the Company uses the aging method to estimate the allowance for anticipated uncollectible receivable balances. Under the aging method, bad debt percentages are determined by management, based on historical experience and the current economic climate, are applied to customers' balances categorized by the number of months the underlying invoices have remained outstanding. At each reporting period, the allowance balance is adjusted to reflect the amount computed as a result of the aging method. When facts subsequently become available to indicate that the allowance provided requires an adjustment, a corresponding adjustment is made to the allowance account as a change in estimate. |
Advances to suppliers | Advances to suppliers Advances to suppliers consist of prepayments to its vendors, such as pharmaceutical manufacturers and other distributors. Since the acquisition of Jiuxin Medicine, the Company have transferred almost all logistics services of its retail drugstores to Jiuxin Medicine. Jiuzhou Pharmacy only directly purchases certain non-medical products, such as certain nutritional supplements. As a result, almost all advances to suppliers are made by Jiuxin Medicine. Advances to suppliers for its drug wholesale business consist of prepayments to its vendors, such as pharmaceutical manufacturers and other distributors. The Company typically receive products from vendors within three to nine months after making prepayments. The Company continuously monitor delivery from, and payments to, its vendors while maintaining a provision for estimated credit losses based upon historical experience and any specific supplier issues, such as discontinuing of inventory supply, that have been identified. |
Inventories | Inventories Inventories are stated at the lower of cost or net realizable value. Cost is determined using the first in first out (FIFO) method. The Company carries out physical inventory counts on a monthly basis at each store and warehouse location. Herbs that the Company farms are recorded at their cost, which includes direct costs such as seed selection, fertilizer, labor costs that are spent in growing herbs on the leased farmland, and indirect costs such as amortization of farmland development cost. All costs are accumulated until the time of harvest and then allocated to harvested herbs costs when the herbs are sold. The Company periodically reviews its inventory and records write-downs to inventories for shrinkage losses and damaged merchandise that are identified. The Company provides a reserve for estimated inventory obsolescence or excess quantities on hand equal to the difference, if any, between the cost of the inventory and its estimated realizable value. |
Farmland assets | Farmland assets Herbs that the Company farms are recorded at their cost, which includes direct costs such as seed selection, fertilizer, and labor costs that are spent in growing herbs on the leased farmland, and indirect costs such as amortization of farmland development costs. Since April 2014, amortization of farmland development costs has been expensed instead of allocated into inventory due to unpredictable future market value of planted gingko trees. All related costs described in the above are accumulated until the time of harvest and then allocated to harvested herbs when they are sold. |
Property and equipment | Property and equipment Property and equipment are stated at cost, net of accumulated depreciation or amortization. Depreciation is calculated on the straight-line method over the estimated useful lives of the assets, taking into consideration the assets' estimated residual value. Leasehold improvements are amortized over the shorter of lease term or remaining lease period of the underlying assets. Following are the estimated useful lives of the Company's property and equipment: Estimated Useful Life Leasehold improvements 3-10 years Motor vehicles 3-5 years Office equipment & furniture 3-5 years Buildings 35 years Maintenance, repairs and minor renewals are charged to expenses as incurred. Major additions and betterment to property and equipment are capitalized. |
Intangible assets | Intangible assets Intangible assets are acquired individually or as part of a group of assets, and are initially recorded at their fair value. The cost of a group of assets acquired in a transaction is allocated to the individual assets based on their relative fair values. The estimated useful lives of the Company's intangible assets are as follows: Estimated Land use rights 50 years Software 3 years L icense Infinite The Company evaluates intangible assets for impairment whenever events or changes in circumstances indicate that the assets might be impaired. |
Impairment of long lived assets | Impairment of long lived assets The Company evaluates long lived tangible and intangible assets for impairment, whenever events or changes in circumstances indicate that the carrying value may not be recoverable from its estimated future cash flows. Recoverability is measured by comparing the assets' net book value to the related projected undiscounted cash flows from these assets, considering a number of factors including past operating results, budgets, economic projections, market trends and product development cycles. If the net book value of the asset exceeds the related undiscounted cash flows, the asset is considered impaired, and a second test is performed to measure the amount of impairment loss. There were no fixed assets and farmland assets impaired for the three months ended June 30, 2020 and 2019. |
Notes payable | Notes payable During the normal course of business, the Company regularly issues bank acceptance bills as a payment method to settle outstanding accounts payables with various material suppliers. The Company records such bank acceptance bills as notes payable. Such notes payable are generally short term in nature due to their short maturity period of six to nine months. |
Income taxes | Income taxes The Company accounts for income taxes following the liability method pursuant to FASB ASC 740 "Income Taxes". Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the period in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if, based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rate is recognized in income in the period that includes the enactment date. The Company also follows FASB ASC 740, which addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. The Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate settlement. ASC 740 also provides guidance on recognition, classification, interest and penalties on income taxes, accounting in interim periods and requires increased disclosures. As of June 30, 2020 and March 31, 2020, the Company did not have a liability for unrecognized tax benefits. It is the Company's policy to include penalties and interest expense related to income taxes as a component of other expense and interest expense, respectively, as necessary. The Company's historical tax years will remain open for examination by the local authorities until the statute of limitations has passed. Under ASC 740-270, entities calculate the income tax provision for an interim period by distinguishing between elements recognized in the income tax provision through (1) applying an estimated annual effective tax rate (ETR) to a measure of year-to-date operating results referred to as "ordinary income (or loss)," and (2) discretely recognizing specific events (referred to as "discrete items") as they occur. Entities should revise the ETR, as necessary, as of the end of each successive interim period during its fiscal year based on changes to any of these estimates and judgments. The ETR expected to apply for the full fiscal year is applied to year-to-date ordinary income (or loss) at the end of each interim period to compute the year-to-date income tax (or benefit) applicable to ordinary income or loss. Income tax expense (or benefit) related to each discrete item is individually determined and recognized in the interim period when the discrete item occurs. As a result, the income tax provision (or benefit) for an interim period might include elements that apply to ordinary income or loss, as well as elements related to discrete items. Discrete items include significant items that are unusual or that occur infrequently. Determining which items are unusual or infrequent often requires a significant degree of judgment. Under ASC 740-270-30-36, entities subject to income taxes in multiple jurisdictions should apply one overall ETR instead of separate ETRs for each jurisdiction when calculating the interim-period income tax or benefit related to consolidated ordinary income (or loss) for the year-to-date interim period, except in certain circumstances. The income tax provision or benefit for each interim period is the difference between the year-to-date amount for the current period and the year-to-date amount for the prior period. |
Value added tax | Value added tax Sales revenue represents the invoiced value of goods, net of VAT. All of the Company's products are sold in the PRC and are subject to a VAT on the gross sales price. The VAT rates range up to 17%, depending on the type of products sold. The VAT may be offset by VAT paid by the Company on raw materials and other materials included in the cost of producing or acquiring its finished products. The Company recorded a VAT payable net of payments in the accompanying financial statements. |
Stock based compensation | Stock based compensation The Company follows the provisions of FASB ASC 718, "Compensation — Stock Compensation," which establishes accounting standards for non-employee and employee stock-based awards. Under the provisions of FASB ASC 718, the fair value of stock issued is used to measure the fair value of services received as the Company believes such approach is a more reliable method of measuring the fair value of the services. For non-employee stock-based awards, fair value is measured based on the value of the Company's common stock on the date that the commitment for performance by the counterparty has been reached or the counterparty's performance is complete. The fair value of the equity instrument is calculated and then recognized as compensation expense over the requisite performance period. For employee stock-based awards, share-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense with graded vesting on a straight–line basis over the requisite service period for the entire award. |
Advertising and promotion costs | Advertising and promotion costs Advertising and promotion costs are expensed as incurred and amounted to $77,068 and $80,049 for the three months ended June 30, 2020 and 2019, respectively. Such costs consist primarily of print and promotional materials such as flyers to local communities. |
Foreign currency translation | Foreign currency translation The Company uses the United States dollar ("U.S. dollars" or "USD") for financial reporting purposes. The Company's subsidiaries and VIEs maintain their books and records in their functional currency the Renminbi ("RMB"), the currency of the PRC. In general, for consolidation purposes, the Company translates the assets and liabilities of its subsidiaries and VIEs into U.S. dollars using the applicable exchange rates prevailing at the balance sheet date, and the statements of income and cash flows are translated at average exchange rates during the reporting period. As a result, amounts related to assets and liabilities reported on the statement of cash flows will not necessarily agree with changes in the corresponding balances on the balance sheet. Equity accounts are translated at historical rates. Adjustments resulting from the translation of the financial statements of the subsidiaries and VIEs are recorded as accumulated other comprehensive income. The balance sheet amounts, with the exception of equity, at June 30, 2020 and at March 31, 2020 were translated at 1 RMB to 0.1414 USD and at 1 RMB to 0.1410 USD, respectively. The average translation rates applied to income and cash flow statement amounts for the three months ended June 30, 2020 and 2019 were at 1 RMB to 0.1411 USD and at 1 RMB to 0.1466 USD, respectively. |
Concentrations and credit risk | Concentrations and credit risk Certain financial instruments, which subject the Company to concentration of credit risk, consist of cash and restricted cash. The Company has cash balances at financial institutions located in Hong Kong and PRC. Balances at financial institutions in Hong Kong may, from time to time, exceed Hong Kong Deposit Protection Board's insured limits. Since March 31, 2015, balances at financial institutions and state-owned banks within the PRC are covered by insurance up to RMB 500,000 (USD 72,800) per bank. As of June 30, 2020 and March 31, 2020, the Company had deposits totaling $24,279,528 and $30,974,714 that were covered by such limited insurance, respectively. Any balance over RMB 500,000 (USD 72,800) per bank in PRC will not be covered. To date, the Company has not experienced any losses in such accounts. For the three months ended June 30, 2020, two vendors accounted for 35.0% of the Company's total purchases and two vendors accounted for more than 10% of total advances to suppliers. For the three months ended June 30, 2019, two vendors accounted for 49.2% of the Company's total purchases and two vendors accounted for more than 10% of total advances to suppliers. For the three months ended June 30, 2020, no customer accounted for more than 10% of the Company's total sales and more than 10% of total accounts receivable. For the three months ended June 30, 2019, no customer accounted for more than 10% of the Company's total sales or more than 10% of total accounts receivable. |
Leases | Leases In February 2016, the FASB issued ASU 2016-02, Leases The Company adopted this new accounting standard on April 1, 2019 on a modified retrospective basis and applied the new standard to all leases through a cumulative-effect adjustment to beginning retained earnings. As a result, comparative financial information has not been restated and continues to be reported under the accounting standards in effect for those periods. The Company elected the package of practical expedients permitted under the transition guidance within the new standard, which includes, among other things, the ability to carry forward the existing lease classification. On April 1, 2019, the Company recorded an after-tax transition adjustment to increase retained earnings by approximately $422,354. The new standard had a material impact on the unaudited condensed consolidated balance sheet, but did not materially impact the Company's consolidated operating results and had no impact on the Company's cash flows. The following is a discussion of the Company's lease policy under the new lease accounting standard: The Company determines if an arrangement contains a lease at the inception of a contract. Right-of-use assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. Right-of-use assets and lease liabilities are recognized at the commencement date based on the present value of the remaining future minimum lease payments. As the interest rate implicit in the Company's leases is not readily determinable, the Company utilizes its incremental borrowing rate, determined by class of underlying asset, to discount the lease payments. The operating lease right-of-use assets also include lease payments made before commencement and exclude lease incentives. The Company leases premises for retail drugstores, and offices under non-cancellable operating leases. Operating lease payments are expensed over the term of lease using straight line method. A majority of the Company's retail drugstore leases have a 3 to 10 year term. Usually within one to three months prior to the expiration date of a lease, the Company is required to notify the lessor and has a priority to continue renting the lease property if a lessor intends to lease property. The lease itself does not have restriction or covenants. If both parties agree to continue, a new lease contract with new lease terms has to been signed by both parties. Usually the rent may increase year by year based on the lease contract. Sublease is typically not allowed. Any damage, if made by the lessee, to the property and equipment within the property has to been fixed or reimbursed by the lessee. The Company does not have any leases entered into but which have not yet commenced. The Company has historically been able to renew a majority of its drugstores leases. The weighted average remaining lease term is 3.2 years and the weighted average discount rate is 4.19%. Under the terms of the lease agreements, the Company has no legal or contractual asset retirement obligations at the end of the leases. See Note 14 "Leases" for additional information. |
Recent Accounting Pronouncements | Recent Accounting Pronouncements Accounting pronouncements adopted In June 2016, the FASB issued ASU 2016-13, "Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments," providing financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. For public business entities that are U.S. Securities and Exchange Commission (SEC) filers, the amendments in this Update are effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. The FASB has voted to defer the effective date for public companies that are smaller reporting companies to fiscal years beginning after December 15, 2022. All entities may adopt the amendments in this Update earlier as of the fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. We are currently evaluating the impact of the adoption of ASU 2016-13 on our consolidated financial statements. In August 2018, the FASB issued ASU 2018-13 Disclosure Framework — Changes to the Disclosure Requirements for Fair Value Measurement, which eliminates, adds, and modifies certain disclosure requirements for fair value measurements under ASC 820. This ASU is to be applied on a prospective basis for certain modified or new disclosure requirements, and all other amendments in the standard are to be applied on a retrospective basis. The new standard is effective for interim and annual periods beginning after December 15, 2019, with early adoption permitted. ASU 2018-13 has no impact on its consolidated financial statements. In January 2017, the FASB issued ASU No. 2017-04, "Intangibles—Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment" ("ASU 2017-04"), which removes Step 2 from the goodwill impairment test. An entity will apply a one-step quantitative test and record the amount of goodwill impairment as the excess of a reporting unit's carrying amount over its fair value, not to exceed the total amount of goodwill allocated to the reporting unit. The new guidance does not amend the optional qualitative assessment of goodwill impairment. Public business entity that is a U.S. Securities and Exchange Commission filer should adopt the amendments in this ASU for its annual or any interim goodwill impairment test in fiscal years beginning after December 15, 2019. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The Company adopted ASU 2017-04 on January 1, 2020. The adoption of the ASU 2017-04 did not have a material impact on the Company's consolidated financial statements. Accounting pronouncements not yet effective to adopt In December 2019, the FASB issued ASU No. 2019-12, "Income Taxes" (Topic 740): Simplifying the Accounting for Income Taxes ("ASU 2019-12"). ASU 2019-12 will simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments also improve consistent application of and simplify GAAP for other areas of Topic 740 by clarifying and amending existing guidance. For public business entities, the amendments in this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2021, and interim periods within fiscal years beginning after December 15, 2022. The Company does not expect that the requirements of ASU 2019-12 will have a material impact on its consolidated financial statements. |
Description of Business and O_2
Description of Business and Organization (Tables) | 3 Months Ended |
Jun. 30, 2020 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Schedule of consolidated financial statements activities | Entity Name Background Ownership Renovation ● Incorporated in Hong Kong SAR on September 2, 2008 100% Jiuxin Management ● Established in the PRC on October 14, 2008 ● Deemed a wholly foreign owned enterprise ("WFOE") under PRC law ● Registered capital of $14.5 million fully paid 100% Shouantang Technology ● Established in the PRC on July 16, 2010 by Renovation with registered capital of $20 million ● Registered capital requirement reduced by the SAIC to $11 million in July 2012 and is fully paid ● Deemed a WFOE under PRC law ● Invests and finances the working capital of Quannuo Technology 100% Qianhong Agriculture ● Established in the PRC on August 10, 2010 by Jiuxin Management ● Registered capital of RMB 10 million fully paid ● Carries out herb farming business 100% Jiuzhou Pharmacy (1) ● Established in the PRC on September 9, 2003 ● Registered capital of RMB 5 million fully paid ● Operates the "Jiuzhou Grand Pharmacy" stores in Hangzhou VIE by contractual arrangements (2) Jiuzhou Clinic (1) ● Established in the PRC as a general partnership on October 10, 2003 ● Operates a medical clinic adjacent to one of Jiuzhou Pharmacy's stores VIE by contractual arrangements (2) Jiuzhou Service (1) ● Established in the PRC on November 2, 2005 ● Registered capital of RMB 500,000 fully paid ● Operates a medical clinic adjacent to one of Jiuzhou Pharmacy's stores VIE by contractual arrangements (2) Jiuxin Medicine ● Established in PRC on December 31, 2003 ● Acquired by Jiuzhou Pharmacy in August 2011 ● 10% of shares sold On April 20, 2018 ● Registered capital of RMB 10 million fully paid ● Carries out pharmaceutical distribution services VIE by contractual arrangements as a wholly-owned subsidiary of Jiuzhou Pharmacy (2) Jiutong Medical ● Established in the PRC on December 20, 2011 by Renovation ● Registered capital of $2.6 million fully paid ● Currently has no operation 100% Entity Name Background Ownership Shouantang Bio ● Established in the PRC in October, 2014 by Shouantang Technology ● 100% held by Shouantang Technology ● Registered capital of RMB 1,000,000 fully paid ● Sells nutritional supplements under its own brand name 100% Jiuyi Technology ● Established in the PRC on September 10, 2015 ● 100% held by Renovation ● Technical support to online pharmacy 100% Kahamadi Bio ● Established in the PRC in May 2016 ● 49% held by Shouantang Bio ● Registered capital of RMB 10 million ● Develop brand name for nutritional supplements 49% Lin'An Jiuzhou ● Established in the PRC in March 31, 2017 ● 100% held by Jiuxin Management ● Registered capital of RMB 5 million ● Explore retail pharmacy market in Lin'An City 100% Linjia Medical ● Established in the PRC in September27, 2017 ● 51% held by Jiuzhou Pharmacy ● Registered capital of RMB 20 million ● Operates local clinics VIE by contractual arrangements as a controlled subsidiary of Jiuzhou Pharmacy (2) Ayi Health ● Established in the PRC in March 29, 2019 ● 51% held by Jiuzhou Pharmacy ● Registered capital of RMB 10 million ● Provide technical Support for medial service VIE by contractual arrangements as a controlled subsidiary of Jiuzhou Pharmacy (2) (1) Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service had been under the common control of Mr. Lei Liu and Ms. Li Qi, the three shareholders (the "Owners") since their respective establishment dates, pursuant to agreements among the Owners to vote their interests in concert as memorialized in a voting rights agreement. Based on such voting agreement, the Company has determined that common control exists among these three companies. The Owners have operated these three companies in conjunction with one another since each company's respective establishment date. Jiuxin Medicine is also deemed under the common control of the Owners as a subsidiary of Jiuzhou Pharmacy. (2) To comply with certain foreign ownership restrictions of pharmacy and medical clinic operators, Jiuxin Management entered into a series of contractual arrangements with Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service on August 1, 2009. These contractual arrangements are comprised of five agreements: a consulting services agreement, operating agreement, equity pledge agreement, voting rights agreement and option agreement. Because such agreements obligate Jiuxin Management to absorb all of the risks of loss from the activities of Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service, and enable the Company (through Jiuxin Management) to receive all of their expected residual returns, the Company accounts for each of the three companies (as well as subsidiaries of Jiuzhou Pharmacy) as a variable interest entity ("VIE") under the accounting standards of the Financial Accounting Standards Board ("FASB"). Accordingly, the financial statements of Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service, as well as the subsidiaries under the control of Jiuzhou Pharmacy, Jiuxin Medicine and Shouantang Bio are consolidated into the financial statements of the Company. |
Summary of Significant Accoun_3
Summary of Significant Accounting Policies (Tables) | 3 Months Ended |
Jun. 30, 2020 | |
Accounting Policies [Abstract] | |
Schedule of fair values of derivative instruments | Active Market Observable Unobservable Total Cash, cash equivalents and restricted cash $ 33,572,328 - - 33,572,328 Financial assets available for sale - - 157,644 157,644 Account receivable 8,984,595 - - 8,984,595 Notes receivable 28,290 - - 28,290 Other receivable 5,599,565 - - 5,599,565 Accounts payable 16,107,594 - - 16,107,594 Notes payable - 26,715,374 - 26,715,374 Other payable 2,176,992 - - 2,176,992 Long-term loan payable - 5,851,778 - 5,851,778 Employee Deposits - - 14,145 14,145 Warrants liability - 68,980 - 68,980 Total $ 66,469,364 32,636,132 171,789 99,277,285 |
Schedule of revenue by major source in each segment | For the three months ended June 30 2020 2019 Retail drugstores Prescription drugs $ 7,406,774 $ 5,695,286 OTC drugs 6,818,484 7,240,228 Nutritional supplements 1,347,769 1,231,133 TCM 949,012 1,104,050 Sundry products 422,551 298,198 Medical devices 1,865,884 1,166,093 Total retail revenue $ 18,810,474 $ 16,734,988 Online pharmacy Prescription drugs $ 1,869,643 $ - OTC drugs 1,322,811 1,024,602 Nutritional supplements 221,031 107,194 TCM 23,199 13,681 Sundry products 546,720 438,736 Medical devices 929,430 859,392 Total online revenue $ 4,912,834 $ 2,443,605 Drug wholesale Prescription drugs $ 5,966,148 $ 4,880,491 OTC drugs 915,146 1,074,261 Nutritional supplements 59,841 21,691 TCM 28,967 98,828 Sundry products 2,597 5,682 Medical devices 358,305 21,238 Total wholesale revenue $ 7,331,004 $ 6,102,191 Total revenue $ 31,054,312 $ 25,280,784 |
Schedule of receivables and contract liabilities from contracts with customers | June 30, March 31, Trade receivable(included in accounts receivable, net) $ 8,984,595 $ 9,770,656 Contract liabilities (included in accrued expenses) 1,112,508 1,106,982 |
Schedule of cash equivalents and restricted cash | June 30, March 31, Cash and cash equivalents $ 18,477,212 $ 16,176,318 Restricted cash 15,095,116 14,806,288 Cash, cash equivalents and restricted cash $ 33,572,328 $ 30,982,606 |
Schedule of estimated useful lives of property and equipment | Estimated Useful Life Leasehold improvements 3-10 years Motor vehicles 3-5 years Office equipment & furniture 3-5 years Buildings 35 years |
Schedule of estimated useful lives of intangible assets | Estimated Land use rights 50 years Software 3 years L icense Infinite |
Trade Accounts Receivable (Tabl
Trade Accounts Receivable (Tables) | 3 Months Ended |
Jun. 30, 2020 | |
Receivables [Abstract] | |
Schedule of trade accounts receivable | June 30, March 31, Accounts receivable $ 11,378,909 $ 12,034,726 Less: allowance for doubtful accounts (2,394,314 ) (2,264,070 ) Trade accounts receivable, net $ 8,984,595 $ 9,770,656 |
Other Current Assets (Tables)
Other Current Assets (Tables) | 3 Months Ended |
Jun. 30, 2020 | |
Prepaid Expense and Other Assets, Current [Abstract] | |
Schedule of other current assets | June 30, March 31, Rental deposits (1) $ 1,558,965 $ 1,364,975 Prepaid and other current assets 276,962 163,565 Total $ 1,835,927 $ 1,528,540 (1) The balance as of June 30, 2020 and March 31, 2020 includes short-term refundable rental security deposits. |
Property and Equipment (Tables)
Property and Equipment (Tables) | 3 Months Ended |
Jun. 30, 2020 | |
Property, Plant and Equipment [Abstract] | |
Schedule of property and equipment | June 30, March 31, Building $ 5,898,768 $ 5,880,627 Leasehold improvements 9,397,190 9,209,136 Farmland development cost 1,691,632 1,686,430 Office equipment and furniture 5,587,888 5,632,955 Motor vehicles 505,883 504,327 Total 23,081,361 22,913,475 Less: Accumulated depreciation (13,758,940 ) (13,059,852 ) Impairment* (2,226,731 ) (2,219,883 ) Property and equipment, net $ 7,095,690 $ 7,633,740 * The variance of impairment from March 31, 2020 to June 30, 2020 is solely caused by exchange rate variance. |
Long-Term Investment (Tables)
Long-Term Investment (Tables) | 3 Months Ended |
Jun. 30, 2020 | |
Debt Disclosure [Abstract] | |
Schedule of long-term investment | June 30, March 31, Kahamadi Bio (1) $ 3,214 * $ 6,217 * Zhetong Medical (2) 3,960,544 2,538,234 Advance to suppliers, net $ 3,963,758 $ 2,544,451 (1) It represents 49% investment in Kahamadi Bio. The investment is recorded using the equity method. Kahamadi Bio suffered loss of $3,015 the three months ended June 30, 2020. (2) It represents 39% investment in Zhejiang Zhetong Medical Co., Ltd. Zhetong Medical was established in March 2020 to target potential acquisitions or cooperate with local pharmacies. By attracting more funds from local investors, the Company expects to continue growing its local network in the future. |
Advances to Suppliers (Tables)
Advances to Suppliers (Tables) | 3 Months Ended |
Jun. 30, 2020 | |
Advances to Suppliers [Abstract] | |
Schedule of advance to suppliers | June 30, March 31, Advance to suppliers $ 3,160,046 $ 2,198,863 Less: allowance for unrefundable advances (922,326 ) (1,024,063 ) Advance to suppliers, net $ 2,237,720 $ 1,174,800 |
Farmland Assets (Tables)
Farmland Assets (Tables) | 3 Months Ended |
Jun. 30, 2020 | |
Farmland Assets [Abstract] | |
Schedule of farmland assets | June 30, March 31, 2020 2020 Farmland assets $ 2,191,944 $ 2,177,606 Less: Impairment* (1,439,687 ) (1,435,259 ) Farmland assets, net $ 752,257 $ 742,347 * As of March 31, 2018, the book value of the Ginkgo trees planted in Qianhong Agriculture's farmland, including their cultivation cost and land lease amortization expense, was approximately $2,416,839. Based on an independent appraisal report, the value of the Ginkgo trees was approximately $796,286 as of March 31, 2018. As a result, the Company recorded an agricultural inventory impairment of $1,620,553 as of March 31, 2018. The difference between the recorded impairment loss and impairment balance in the above is primarily due to the exchange rate variance over years. There are no leasehold impairment expense in the three months ended June 30, 2020 and 2019. |
Other Noncurrent Assets (Tables
Other Noncurrent Assets (Tables) | 3 Months Ended |
Jun. 30, 2020 | |
Other Assets, Noncurrent Disclosure [Abstract] | |
Schedule of other noncurrent assets | June 30, March 31, Forest land use rights* $ 985,156 $ 994,558 Others 64,028 52,205 Total $ 1,049,184 $ 1,046,763 * The prepayment for lease of forest land use rights is a payment made to a local government in connection with entering into an operating land lease agreement. The land is currently used to cultivate Ginkgo trees. The forest rights certificate from the local village extends the life of the lease to January 31, 2060. |
Schedule of amortizations of the prepayment for lease of land use right | For the year ending June 30, Amount 2021 $ 26,515 2022 26,515 2023 26,515 2024 26,515 2025 26,515 Thereafter 852,581 |
Leases (Tables)
Leases (Tables) | 3 Months Ended |
Jun. 30, 2020 | |
Leases [Abstract] | |
Schedule of cash flow information related to leases | Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows paid for operating leases $ 1,671,118 Right-of-use assets obtained in exchange for lease obligations: Operating leases - |
Schedule of condensed balance sheet related to leases | Operating leases: Operating lease right-of-use assets $ 19,351,247 Current portion of operating lease liabilities $ 466,213 Long-term operating lease liabilities 16,917,159 Total operating lease liabilities $ 17,383,372 Weighted average remaining lease term Operating leases 3.2 Weighted average discount rate Operating leases 4.19 % |
Schedule of lease liabilities under operating leases | Operating For the year ending June 30, Leases 2021 $ 485,355 2022 6,345,189 2023 4,510,762 2024 3,277,971 2025 1,995,568 Thereafter 2,575,035 Total lease payments 19,189,880 Less: imputed interest (1,806,508 ) Total lease liabilities $ 17,383,372 |
Intangible Assets (Tables)
Intangible Assets (Tables) | 3 Months Ended |
Jun. 30, 2020 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Schedule of net intangible assets | June 30, March 31, License (1) $ 2,246,880 $ 2,220,512 Software (2) 1,086,366 1,083,024 Land use rights (3) 1,379,337 1,375,095 Total intangible assets 4,712,583 4,678,631 Less: accumulated amortization (735,234 ) (667,633 ) Less: impairment (4) (618,942 ) (617,038 ) Intangible assets, net $ 3,358,407 $ 3,393,960 Amortization expense of intangibles amounted to $65,389 and $58,466 for the three months ended June 30, 2020 and 2019, respectively. (1) This represents the fair value of the licenses of insurance applicable drugstores acquired from a variety of drugstores such as Sanhao Pharmacy and several local stores. The licenses allow patients to pay by using insurance cards at stores. The stores are reimbursed from the Human Resource and Social Security Department of Hangzhou City. In 2014, the Company acquired Sanhao Pharmacy, a drugstore chain. In September 2017, the Company acquired several new stores for the purpose of the Municipal Social Medical Reimbursement Qualification Certificates. On January 9, 2020, the Company acquired a local drugstore chain. The acquired drugstores ceased their stores' business and liquidate all of the stores' accounts after Jiuzhou Pharmacy acquired them. In March 2020, the drugstore chain has dissolved and its certificates were transferred to new stores opened at the same time. (2) These balances primarily include the SAP ERP system, the Internet Clinic Diagnosis Terminal system and the Chronic Disease Management system. In 2017, we have installed a leading ERP system, SAP from Germany. SAP is a well-known management system used by many fortune 500 companies. It is being amortized over three years since its installation. In 2020, we have installed an internet Clinic Diagnosis System used to strengthen our ability to perform online diagnosis which may increase more customer spending and a Chronic Disease Management System used to better manage and monitor our members' health. As of June 30, 2020, the SAP system has a net value of $135,698 (RMB 959,352), the internet Clinic Diagnosis System has a net value of approximately $380,313 (RMB 2,688,709), the Chronic Disease Management System has a net value of approximately $16,462 (RMB 116,379) . (3) In July 2013, the Company purchased the land use rights of a plot of land in Lin'an, Hangzhou, intended for the establishment of an herb processing plant in the future. However, as the Company's farming business in Lin'an has not grown, the Company does not expect completion of the plant in the near future. (4) In the year ended March 31, 2020, the company evaluated the licenses of insurance applicable drugstores acquired in the past based on the discounted positive cash value. Due to the stricter government insurance policy in fiscal year 2021, the value of these licenses has declined. As a result, the company recorded an impairment. There are no impairment expense in the three months ended June 30, 2020 and 2019. |
Notes Payable (Tables)
Notes Payable (Tables) | 3 Months Ended |
Jun. 30, 2020 | |
Notes Payable [Abstract] | |
Schedule of credit facilities with banks | Origination Maturity June 30, March 31, Beneficiary Endorser date date 2020 2020 Jiuzhou Pharmacy(1) HUB 10/09/19 04/09/20 - 3,478,259 Jiuzhou Pharmacy(1) HUB 11/06/19 05/06/20 - 164,582 Jiuzhou Pharmacy(1) HUB 12/05/19 06/05/20 - 3,106,474 Jiuzhou Pharmacy(1) HUB 12/31/19 06/30/20 - 2,289,308 Jiuzhou Pharmacy(1) HUB 01/06/20 07/06/20 129,856 129,457 Jiuzhou Pharmacy(1) HUB 02/19/20 08/19/20 5,120,844 5,105,096 Jiuzhou Pharmacy(1) HUB 03/10/20 09/10/20 5,341,297 5,324,871 Jiuxin Medicine(1) HUB 12/26/19 06/26/20 - 1,371,992 Jiuxin Medicine(1) HUB 12/31/19 06/30/20 3,943,776 Jiuxin Medicine(1) HUB 03/31/20 09/30/20 1,697,376 1,692,156 Jiuzhou Pharmacy(1) HUB 04/10/20 10/10/20 2,969,129 Jiuzhou Pharmacy(1) HUB 04/29/20 10/29/20 546,874 Jiuzhou Pharmacy(1) HUB 05/09/20 11/09/20 3,803,552 - Jiuzhou Pharmacy(1) HUB 06/24/20 12/24/20 1,405,995 - Jiuzhou Pharmacy(1) HUB 06/30/20 12/30/20 891,122 - Jiuxin Medicine(1) HUB 06/30/20 12/30/20 4,809,329 - Total $ 26,715,374 $ 26,605,971 (1) As of June 30, 2020, the Company had $26,715,374 (RMB 188,870,639) of notes payable from HUB. The Company is required to hold restricted cash in the amount of $14,913,825 (RMB 105,684,113) with HUB as collateral against these bank notes. Included in the restricted cash is a total of $8,770,422 three-year deposit (RMB 62,150,000) deposited into HUB as a collateral for current and future notes payable from HUB. As of March 31, 2020, the Company had $26,605,971 (RMB 188,677,437) of notes payable from HUB. The Company is required to hold restricted cash in the amount of $14,596,179 (RMB 103,509,456) with HUB as collateral against these bank notes. Included in the restricted cash is a total of $8,763,958 three-year deposit (RMB 62,150,000) deposited into HUB as a collateral for current and future notes payable from HUB. |
Related Party Transactions an_2
Related Party Transactions and Arrangements (Tables) | 3 Months Ended |
Jun. 30, 2020 | |
Related Party Transactions [Abstract] | |
Schedule of amounts payable to related parties | June 30, March 31, Due to a director and CEO (1) 491,300 490,218 (1) Due to foreign exchange restrictions, the Company's director and CEO, Mr. Lei Liu personally lent U.S. dollars to the Company to facilitate its payments of expenses in the United States. |
Warrants (Tables)
Warrants (Tables) | 3 Months Ended |
Jun. 30, 2020 | |
Warrants [Abstract] | |
Schedule of estimated fair value of warrants using the binominal pricing model | Common Stock Common Stock June 30, March 31, Stock price $ 1.44 $ 1.77 Exercise price $ 3.10 $ 3.10 Annual dividend yield - % - % Expected term (years) 0.56 0.81 Risk-free interest rate 0.18 % 0.71 % Expected volatility 98.86 % 62.08 % |
Loss Per Share (Tables)
Loss Per Share (Tables) | 3 Months Ended |
Jun. 30, 2020 | |
Loss Per Share [Abstract] | |
Schedule of reconciliation of the basic and diluted (loss) earnings per share | The three months ended 2020 2019 Net loss attributable to controlling interest $ (231,509 ) $ (2,134,951 ) Weighted average shares used in basic computation 34,428,271 32,453,269 Diluted effect of stock options and warrants - - Weighted average shares used in diluted computation 34,428,271 32,453,269 Loss per share – Basic: - - Net loss attributable to controlling interest $ (0.01 ) $ (0.07 ) Loss per share – Diluted: Net loss attributable to controlling interest $ (0.01 ) $ (0.07 ) |
Segments (Tables)
Segments (Tables) | 3 Months Ended |
Jun. 30, 2020 | |
Segment Reporting [Abstract] | |
Summary of segment of the continuing operations | Retail drugstores Online Pharmacy Drug wholesale Herb Total Revenue $ 18,810,474 $ 4,912,834 7,331,004 - 31,054,312 Cost of goods 12,402,182 4,228,411 6,443,500 - 23,074,093 Gross profit $ 6,408,292 $ 684,423 887,504 - 7,980,219 Selling expenses 4,977,047 704,876 590,484 - 6,272,407 General and administrative expenses 1,128,083 59,011 933,072 - 2,120,166 Loss from operations $ 303,162 $ (79,464 ) (636,052 ) - (412,354 ) Depreciation and amortization $ 750,498 $ - 10,042 - 760,540 Total capital expenditures $ 169,807 $ - - 169,807 Retail drugstores Online Pharmacy Drug wholesale Herb Total Revenue $ 16,734,988 $ 2,443,605 6,102,191 - 25,280,784 Cost of goods 11,682,721 2,096,850 5,439,775 - 19,219,346 Gross profit $ 5,052,267 $ 346,755 662,416 - 6,061,438 Selling expenses 4,835,666 473,380 659,505 - 5,968,551 General and administrative expenses 1,733,704 55,123 1,062,785 - 2,851,612 Loss from operations $ (1,517,103 ) $ (181,748 ) (1,059,874 ) - (2,758,725 ) Depreciation and amortization $ 504,463 $ - 8,486 - 512,949 Total capital expenditures $ 753,173 $ - - 753,173 |
Summary of net revenue from external customers through its retail drugstores by main products | For the three months ended June 30, 2020 2019 Prescription drugs $ 7,406,774 $ 5,695,286 OTC drugs 6,818,484 7,240,228 Nutritional supplements 1,347,769 1,231,133 TCM 949,012 1,104,050 Sundry products 422,551 298,198 Medical devices 1,865,884 1,166,093 Total $ 18,810,474 $ 16,734,988 For the three months ended June 30, 2020 2019 Prescription drugs $ 1,869,643 $ - OTC drugs 1,322,811 1,024,602 Nutritional supplements 221,031 107,194 TCM 23,199 13,681 Sundry products 546,720 438,736 Medical devices 929,430 859,392 Total $ 4,912,834 $ 2,443,605 For the three months ended June 30, 2020 2019 Prescription drugs $ 5,966,148 $ 4,880,491 OTC drugs 915,146 1,074,261 Nutritional supplements 59,841 21,691 TCM 28,967 98,828 Sundry products 2,597 5,682 Medical devices 358,305 21,238 Total $ 7,331,004 $ 6,102,191 |
Description of Business and O_3
Description of Business and Organization (Details) | 3 Months Ended | |
Jun. 30, 2020 | ||
Variable Interest Entity [Line Items] | ||
Entity ownership percentage | 100.00% | |
Renovation [Member] | ||
Variable Interest Entity [Line Items] | ||
Ownership background, description | Incorporated in Hong Kong SAR on September 2, 2008 | |
Entity ownership percentage | 100.00% | |
Jiuxin Management [Member] | ||
Variable Interest Entity [Line Items] | ||
Ownership background, description | Established in the PRC on October 14, 2008 Deemed a wholly foreign owned enterprise ("WFOE") under PRC law Registered capital of $14.5 million fully paid | |
Entity ownership percentage | 100.00% | |
Shouantang Technology [Member] | ||
Variable Interest Entity [Line Items] | ||
Ownership background, description | Established in the PRC on July 16, 2010 by Renovation with registered capital of $20 million Registered capital requirement reduced by the SAIC to $11 million in July 2012 and is fully paid Deemed a WFOE under PRC law Invests and finances the working capital of Quannuo Technology | |
Entity ownership percentage | 100.00% | |
Qianhong Agriculture [Member] | ||
Variable Interest Entity [Line Items] | ||
Ownership background, description | Established in the PRC on August 10, 2010 by Jiuxin Management Registered capital of RMB 10 million fully paid Carries out herb farming business | |
Entity ownership percentage | 100.00% | |
Jiuzhou Pharmacy [Member] | ||
Variable Interest Entity [Line Items] | ||
Ownership background, description | Established in the PRC on September 9, 2003 Registered capital of RMB 5 million fully paid Operates the "Jiuzhou Grand Pharmacy" stores in Hangzhou | [1] |
Entity ownership description | VIE by contractual arrangements | [1],[2] |
Jiuzhou Clinic [Member] | ||
Variable Interest Entity [Line Items] | ||
Ownership background, description | Established in the PRC as a general partnership on October 10, 2003 Operates a medical clinic adjacent to one of Jiuzhou Pharmacy's stores | [1] |
Entity ownership description | VIE by contractual arrangements | [1],[2] |
Jiuzhou Service [Member] | ||
Variable Interest Entity [Line Items] | ||
Ownership background, description | Established in the PRC on November 2, 2005 Registered capital of RMB 500,000 fully paid Operates a medical clinic adjacent to one of Jiuzhou Pharmacy's stores | [1] |
Entity ownership description | VIE by contractual arrangements | [1],[2] |
Jiuxin Medicine [Member] | ||
Variable Interest Entity [Line Items] | ||
Ownership background, description | Established in PRC on December 31, 2003 Acquired by Jiuzhou Pharmacy in August 2011 10% of shares sold On April 20, 2018 Registered capital of RMB 10 million fully paid Carries out pharmaceutical distribution services | |
Entity ownership description | VIE by contractual arrangements as a wholly-owned subsidiary of Jiuzhou Pharmacy | [2] |
Jiutong Medical [Member] | ||
Variable Interest Entity [Line Items] | ||
Ownership background, description | Established in the PRC on December 20, 2011 by Renovation Registered capital of $2.6 million fully paid Currently has no operation | |
Entity ownership percentage | 100.00% | |
Shouantang Bio [Member] | ||
Variable Interest Entity [Line Items] | ||
Ownership background, description | Established in the PRC in October, 2014 by Shouantang Technology 100% held by Shouantang Technology Registered capital of RMB 1,000,000 fully paid Sells nutritional supplements under its own brand name | |
Entity ownership percentage | 100.00% | |
Jiuyi Technology [Member] | ||
Variable Interest Entity [Line Items] | ||
Ownership background, description | Established in the PRC on September 10, 2015 100% held by Renovation Technical support to online pharmacy | |
Entity ownership percentage | 100.00% | |
Kahamadi Bio [Member] | ||
Variable Interest Entity [Line Items] | ||
Ownership background, description | Established in the PRC in May 2016 49% held by Shouantang Bio Registered capital of RMB 10 million Develop brand name for nutritional supplements | |
Entity ownership percentage | 49.00% | |
Lin’An Jiuzhou [Member] | ||
Variable Interest Entity [Line Items] | ||
Ownership background, description | Established in the PRC in March 31, 2017 100% held by Jiuxin Management Registered capital of RMB 5 million Explore retail pharmacy market in Lin'An City | |
Entity ownership percentage | 100.00% | |
Linjia Medical [Member] | ||
Variable Interest Entity [Line Items] | ||
Ownership background, description | Established in the PRC in September 27, 2017 51% held by Jiuzhou Pharmacy Registered capital of RMB 20 million Operates local clinics | |
Entity ownership description | VIE by contractual arrangements as a controlled subsidiary of Jiuzhou Pharmacy | [2] |
Ayi Health [Member] | ||
Variable Interest Entity [Line Items] | ||
Ownership background, description | Established in the PRC in March 29, 2019 51% held by Jiuzhou Pharmacy Registered capital of RMB 10 million Provide technical Support for medial service | |
Entity ownership description | VIE by contractual arrangements as a controlled subsidiary of Jiuzhou Pharmacy | [2] |
[1] | Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service had been under the common control of Mr. Lei Liu and Ms. Li Qi, the three shareholders (the "Owners") since their respective establishment dates, pursuant to agreements among the Owners to vote their interests in concert as memorialized in a voting rights agreement. Based on such voting agreement, the Company has determined that common control exists among these three companies. The Owners have operated these three companies in conjunction with one another since each company's respective establishment date. Jiuxin Medicine is also deemed under the common control of the Owners as a subsidiary of Jiuzhou Pharmacy. | |
[2] | To comply with certain foreign ownership restrictions of pharmacy and medical clinic operators, Jiuxin Management entered into a series of contractual arrangements with Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service on August 1, 2009. These contractual arrangements are comprised of five agreements: a consulting services agreement, operating agreement, equity pledge agreement, voting rights agreement and option agreement. Because such agreements obligate Jiuxin Management to absorb all of the risks of loss from the activities of Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service, and enable the Company (through Jiuxin Management) to receive all of their expected residual returns, the Company accounts for each of the three companies (as well as subsidiaries of Jiuzhou Pharmacy) as a variable interest entity ("VIE") under the accounting standards of the Financial Accounting Standards Board ("FASB"). Accordingly, the financial statements of Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service, as well as the subsidiaries under the control of Jiuzhou Pharmacy, Jiuxin Medicine and Shouantang Bio are consolidated into the financial statements of the Company. |
Description of Business and O_4
Description of Business and Organization (Details Textual) | 1 Months Ended | 3 Months Ended | ||||||||||
Sep. 17, 2009shares | Jun. 30, 2020USD ($) | Jun. 30, 2020CNY (¥) | Jan. 09, 2020$ / shares | Mar. 29, 2019 | Apr. 20, 2018USD ($) | Apr. 20, 2018CNY (¥) | Mar. 31, 2018USD ($) | Mar. 31, 2018CNY (¥) | May 31, 2016 | Jul. 31, 2012USD ($) | Jul. 16, 2010USD ($) | |
Description of Business and Organization (Textual) | ||||||||||||
Date of incorporation | Dec. 19, 2006 | |||||||||||
Local drugstores price per share | $ / shares | $ 0.14 | |||||||||||
RMB [Member] | ||||||||||||
Description of Business and Organization (Textual) | ||||||||||||
Local drugstores price per share | $ / shares | $ 1 | |||||||||||
Renovation Investment [Member] | ||||||||||||
Description of Business and Organization (Textual) | ||||||||||||
Percentage of capital stock in exchange transaction | 100.00% | |||||||||||
Issuance of equity consideration, shares | shares | 7,900,000 | |||||||||||
Zhejiang Jiuxin Medicine [Member] | ||||||||||||
Description of Business and Organization (Textual) | ||||||||||||
Issuance of equity consideration | $ | $ 79,625 | |||||||||||
Percentage of capital stock in exchange transaction | 51.00% | 51.00% | ||||||||||
Zhejiang Jiuxin Medicine [Member] | RMB [Member] | ||||||||||||
Description of Business and Organization (Textual) | ||||||||||||
Issuance of equity consideration | ¥ 507,760 | |||||||||||
Registered capital paid | ¥ 10,000,000 | |||||||||||
Hangzhou Jiuzhou Grand Pharmacy Chain [Member] | ||||||||||||
Description of Business and Organization (Textual) | ||||||||||||
Percentage of capital stock in exchange transaction | 51.00% | 51.00% | 51.00% | |||||||||
Total amount of investment | $ | $ 741,540 | |||||||||||
Hangzhou Jiuzhou Grand Pharmacy Chain [Member] | RMB [Member] | ||||||||||||
Description of Business and Organization (Textual) | ||||||||||||
Registered capital paid | ¥ 5,000,000 | |||||||||||
Total amount of investment | ¥ 5,100,000 | |||||||||||
Shouantang Bio [Member] | ||||||||||||
Description of Business and Organization (Textual) | ||||||||||||
Percentage of capital stock in exchange transaction | 100.00% | 100.00% | 49.00% | |||||||||
Shouantang Bio [Member] | RMB [Member] | ||||||||||||
Description of Business and Organization (Textual) | ||||||||||||
Registered capital paid | ¥ 1,000,000 | |||||||||||
Jiuxin Medicine [Member] | ||||||||||||
Description of Business and Organization (Textual) | ||||||||||||
Percentage of capital stock in exchange transaction | 10.00% | 10.00% | 10.00% | 10.00% | ||||||||
Zhejiang Jiuxin Investment Management [Member] | ||||||||||||
Description of Business and Organization (Textual) | ||||||||||||
Registered capital paid | $ | $ 14,500,000 | |||||||||||
Hangzhou Qianhong Agriculture Development [Member] | RMB [Member] | ||||||||||||
Description of Business and Organization (Textual) | ||||||||||||
Registered capital paid | ¥ 10,000,000 | |||||||||||
Hangzhou Jiutong Medical Technology [Member] | ||||||||||||
Description of Business and Organization (Textual) | ||||||||||||
Registered capital paid | $ | $ 2,600,000 | |||||||||||
Kahamadi Bio [Member] | ||||||||||||
Description of Business and Organization (Textual) | ||||||||||||
Percentage of capital stock in exchange transaction | 49.00% | 49.00% | ||||||||||
Kahamadi Bio [Member] | RMB [Member] | ||||||||||||
Description of Business and Organization (Textual) | ||||||||||||
Registered capital paid | ¥ 10,000,000 | |||||||||||
Lin'An Jiuzhou [Member] | ||||||||||||
Description of Business and Organization (Textual) | ||||||||||||
Percentage of capital stock in exchange transaction | 100.00% | 100.00% | ||||||||||
Lin'An Jiuzhou [Member] | RMB [Member] | ||||||||||||
Description of Business and Organization (Textual) | ||||||||||||
Registered capital paid | ¥ 5,000,000 | |||||||||||
Ayi Health [Member] | ||||||||||||
Description of Business and Organization (Textual) | ||||||||||||
Percentage of capital stock in exchange transaction | 51.00% | 51.00% | ||||||||||
Ayi Health [Member] | RMB [Member] | ||||||||||||
Description of Business and Organization (Textual) | ||||||||||||
Registered capital paid | ¥ 10,000,000 | |||||||||||
Zhejiang Shouantang Medical Technology [Member] | ||||||||||||
Description of Business and Organization (Textual) | ||||||||||||
Registered capital paid | $ | $ 20,000,000 | |||||||||||
Registered capital requirement reduced | $ | $ 11,000,000 | |||||||||||
Hangzhou Jiuzhou Medical and Public Health Service [Member] | RMB [Member] | ||||||||||||
Description of Business and Organization (Textual) | ||||||||||||
Registered capital paid | ¥ 20,000,000 | |||||||||||
Hangzhou Jiuyi Medical Technology [Member] | ||||||||||||
Description of Business and Organization (Textual) | ||||||||||||
Percentage of capital stock in exchange transaction | 100.00% | 100.00% | ||||||||||
Jiuzhou Service [Member] | RMB [Member] | ||||||||||||
Description of Business and Organization (Textual) | ||||||||||||
Registered capital paid | ¥ 500,000 |
Liquidity (Details)
Liquidity (Details) | Jun. 03, 2020USD ($)$ / sharesshares | Apr. 15, 2019USD ($)$ / sharesshares | Jun. 30, 2020USD ($) | Jun. 30, 2020CNY (¥) |
Liquidity (Textual) | ||||
Bank credit line from two local banks | $ 27,460,000 | |||
Two credit line agreements [Member] | ||||
Liquidity (Textual) | ||||
Bank credit line from two local banks | 740,000 | |||
Two credit line agreements [Member] | Jiuzhou Pharmacy [Member] | ||||
Liquidity (Textual) | ||||
Bank credit line from two local banks | $ 7,175,000 | |||
Two credit line agreements [Member] | Jiuzhou Pharmacy [Member] | RMB [Member] | ||||
Liquidity (Textual) | ||||
Bank credit line from two local banks | ¥ | ¥ 50,000,000 | |||
Private Placement [Member] | ||||
Liquidity (Textual) | ||||
Purchase of aggregate of common stock | shares | 5,000,004 | 4,000,008 | ||
Common stock price, per share | $ / shares | $ 2 | $ 2.50 | ||
Gross proceeds from private placement | $ 10,000,008 | $ 10,000,020 |
Summary of Significant Accoun_4
Summary of Significant Accounting Policies (Details) - USD ($) | Jun. 30, 2020 | Mar. 31, 2020 |
Summary of fair values of derivative instruments | ||
Cash, cash equivalents and restricted cash | $ 33,572,328 | |
Financial assets available for sale | 157,644 | $ 157,159 |
Account receivable | 8,984,595 | |
Notes receivable | 28,290 | |
Other receivable | 5,599,565 | |
Accounts payable | 16,107,594 | |
Notes payable | 26,715,374 | |
Other payable | 2,176,992 | |
Long-term loan payable | 5,851,778 | |
Employee Deposits | 14,145 | |
Warrants liability | 68,980 | |
Total | 99,277,285 | |
Active Market for Identical Assets (Level 1) [Member] | ||
Summary of fair values of derivative instruments | ||
Cash, cash equivalents and restricted cash | 33,572,328 | |
Financial assets available for sale | ||
Account receivable | 8,984,595 | |
Notes receivable | 28,290 | |
Other receivable | 5,599,565 | |
Accounts payable | 16,107,594 | |
Notes payable | ||
Other payable | 2,176,992 | |
Long-term loan payable | ||
Employee Deposits | ||
Warrants liability | ||
Total | 66,469,364 | |
Observable Inputs (Level 2) [Member] | ||
Summary of fair values of derivative instruments | ||
Cash, cash equivalents and restricted cash | ||
Financial assets available for sale | ||
Account receivable | ||
Notes receivable | ||
Other receivable | ||
Accounts payable | ||
Notes payable | 26,715,374 | |
Other payable | ||
Long-term loan payable | 5,851,778 | |
Employee Deposits | ||
Warrants liability | 68,980 | |
Total | 32,636,132 | |
Unobservable Inputs (Level 3) [Member] | ||
Summary of fair values of derivative instruments | ||
Cash, cash equivalents and restricted cash | ||
Financial assets available for sale | 157,644 | |
Account receivable | ||
Notes receivable | ||
Other receivable | ||
Accounts payable | ||
Notes payable | ||
Other payable | ||
Long-term loan payable | ||
Employee Deposits | 14,145 | |
Warrants liability | ||
Total | $ 171,789 |
Summary of Significant Accoun_5
Summary of Significant Accounting Policies (Details 1) - USD ($) | 3 Months Ended | |
Jun. 30, 2020 | Jun. 30, 2019 | |
Disaggregation of Revenue [Line Items] | ||
Total revenue | $ 31,054,312 | $ 25,280,784 |
Retail drugstores [Member] | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | 18,810,474 | 16,734,988 |
Retail drugstores [Member] | Prescription drugs [Member] | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | 7,406,774 | 5,695,286 |
Retail drugstores [Member] | OTC drugs [Member] | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | 6,818,484 | 7,240,228 |
Retail drugstores [Member] | Nutritional supplements [Member] | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | 1,347,769 | 1,231,133 |
Retail drugstores [Member] | TCM [Member] | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | 949,012 | 1,104,050 |
Retail drugstores [Member] | Sundry products [Member] | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | 422,551 | 298,198 |
Retail drugstores [Member] | Medical devices [Member] | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | 1,865,884 | 1,166,093 |
Online pharmacy [Member] | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | 4,912,834 | 2,443,605 |
Online pharmacy [Member] | Prescription drugs [Member] | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | 1,869,643 | |
Online pharmacy [Member] | OTC drugs [Member] | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | 1,322,811 | 1,024,602 |
Online pharmacy [Member] | Nutritional supplements [Member] | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | 221,031 | 107,194 |
Online pharmacy [Member] | TCM [Member] | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | 23,199 | 13,681 |
Online pharmacy [Member] | Sundry products [Member] | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | 546,720 | 438,736 |
Online pharmacy [Member] | Medical devices [Member] | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | 929,430 | 859,392 |
Drug wholesale [Member] | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | 7,331,004 | 6,102,191 |
Drug wholesale [Member] | Prescription drugs [Member] | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | 5,966,148 | 4,880,491 |
Drug wholesale [Member] | OTC drugs [Member] | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | 915,146 | 1,074,261 |
Drug wholesale [Member] | Nutritional supplements [Member] | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | 59,841 | 21,691 |
Drug wholesale [Member] | TCM [Member] | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | 28,967 | 98,828 |
Drug wholesale [Member] | Sundry products [Member] | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | 2,597 | 5,682 |
Drug wholesale [Member] | Medical devices [Member] | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | $ 358,305 | $ 21,238 |
Summary of Significant Accoun_6
Summary of Significant Accounting Policies (Details 2) - USD ($) | Jun. 30, 2020 | Mar. 31, 2020 |
Accounting Policies [Abstract] | ||
Trade receivable(included in accounts receivable, net) | $ 8,984,595 | $ 9,770,656 |
Contract liabilities (included in accrued expenses) | $ 1,112,508 | $ 1,106,982 |
Summary of Significant Accoun_7
Summary of Significant Accounting Policies (Details 3) - USD ($) | Jun. 30, 2020 | Mar. 31, 2020 | Jun. 30, 2019 | Mar. 31, 2019 |
Accounting Policies [Abstract] | ||||
Cash and cash equivalents | $ 18,477,212 | $ 16,176,318 | ||
Restricted cash | 15,095,116 | 14,806,288 | ||
Cash, cash equivalents and restricted cash | $ 33,572,328 | $ 30,982,606 | $ 23,150,153 | $ 24,745,202 |
Summary of Significant Accoun_8
Summary of Significant Accounting Policies (Details 4) | 3 Months Ended |
Jun. 30, 2020 | |
Leasehold improvements [Member] | Minimum [Member] | |
Property, Plant and Equipment [Line Items] | |
Estimated useful lives of property and equipment | 3 years |
Leasehold improvements [Member] | Maximum [Member] | |
Property, Plant and Equipment [Line Items] | |
Estimated useful lives of property and equipment | 10 years |
Motor vehicles [Member] | Minimum [Member] | |
Property, Plant and Equipment [Line Items] | |
Estimated useful lives of property and equipment | 3 years |
Motor vehicles [Member] | Maximum [Member] | |
Property, Plant and Equipment [Line Items] | |
Estimated useful lives of property and equipment | 5 years |
Office equipment & furniture [Member] | Minimum [Member] | |
Property, Plant and Equipment [Line Items] | |
Estimated useful lives of property and equipment | 3 years |
Office equipment & furniture [Member] | Maximum [Member] | |
Property, Plant and Equipment [Line Items] | |
Estimated useful lives of property and equipment | 5 years |
Buildings [Member] | |
Property, Plant and Equipment [Line Items] | |
Estimated useful lives of property and equipment | 35 years |
Summary of Significant Accoun_9
Summary of Significant Accounting Policies (Details 5) | 3 Months Ended |
Jun. 30, 2020 | |
Land use rights [Member] | |
Finite-Lived Intangible Assets [Line Items] | |
Estimated useful life of intangible assets | 50 years |
Software [Member] | |
Finite-Lived Intangible Assets [Line Items] | |
Estimated useful life of intangible assets | 3 years |
License [Member] | |
Finite-Lived Intangible Assets [Line Items] | |
Estimated useful life of intangible assets, description | Infinite |
Summary of Significant Accou_10
Summary of Significant Accounting Policies (Details Textual) | 3 Months Ended | |||||
Jun. 30, 2020USD ($)Vendors | Jun. 30, 2019USD ($)Vendors | Mar. 31, 2020USD ($) | Apr. 02, 2019USD ($) | Mar. 31, 2015USD ($) | Mar. 31, 2015CNY (¥) | |
Summary of Significant Accounting Policies (Textual) | ||||||
Ownership percentage | 100.00% | |||||
Voting ownership interest | 50.00% | |||||
Value added tax, percentage | 17.00% | |||||
Advertising and promotion costs | $ 77,068 | $ 80,049 | ||||
Foreign currency translation, description | The balance sheet amounts, with the exception of equity, at June 30, 2020 and at March 31, 2020 were translated at 1 RMB to 0.1414 USD and at 1 RMB to 0.1410 USD, respectively. The average translation rates applied to income and cash flow statement amounts for the three months ended June 30, 2020 and 2019 were at 1 RMB to 0.1411 USD and at 1 RMB to 0.1466 USD, respectively. | |||||
Insurance covered by own bank | $ 72,800 | |||||
Bank uncovered amount | $ 72,800 | |||||
Deposits | $ 24,279,528 | $ 30,974,714 | ||||
Retained earnings | $ 422,354 | |||||
Weighted average remaining lease term | 3 years 2 months 12 days | |||||
Weighted average discount rate | 4.19% | |||||
Minimum [Member] | Retail Site [Member] | ||||||
Summary of Significant Accounting Policies (Textual) | ||||||
Term of agreement for operating leases | 3 years | |||||
Maximum [Member] | Retail Site [Member] | ||||||
Summary of Significant Accounting Policies (Textual) | ||||||
Term of agreement for operating leases | 10 years | |||||
Cost of Goods, Total [Member] | ||||||
Summary of Significant Accounting Policies (Textual) | ||||||
Concentration risk, percentage | 35.00% | 49.20% | ||||
Number of vendors | Vendors | 2 | 2 | ||||
Advances to Suppliers [Member] | ||||||
Summary of Significant Accounting Policies (Textual) | ||||||
Concentration risk, percentage | 10.00% | 10.00% | ||||
Number of vendors | Vendors | 2 | 2 | ||||
Accounts Receivable [Member] | ||||||
Summary of Significant Accounting Policies (Textual) | ||||||
Concentration risk, percentage | 10.00% | 10.00% | ||||
Sales Revenue, Net [Member] | ||||||
Summary of Significant Accounting Policies (Textual) | ||||||
Concentration risk, percentage | 10.00% | 10.00% | ||||
RMB [Member] | ||||||
Summary of Significant Accounting Policies (Textual) | ||||||
Insurance covered by own bank | ¥ | ¥ 500,000 | |||||
Bank uncovered amount | ¥ | ¥ 500,000 |
Financial Assets Available fo_2
Financial Assets Available for Sale (Details) | Jun. 30, 2020USD ($) | Jun. 30, 2020CNY (¥) | Mar. 31, 2020USD ($) | Mar. 31, 2020CNY (¥) |
Financial Assets Available for Sale (Textual) | ||||
Financial assets available for sale | $ | $ 157,644 | $ 157,159 | ||
Retail Pharmaceutical Busines [Member] | ||||
Financial Assets Available for Sale (Textual) | ||||
Invested total amount | $ | 72,551 | |||
Songlu Pharmaceutical [Member] | ||||
Financial Assets Available for Sale (Textual) | ||||
Invested total amount | $ | $ 84,608 | |||
Percentage of shares | 0.50% | 0.50% | ||
RMB [Member] | ||||
Financial Assets Available for Sale (Textual) | ||||
Financial assets available for sale | ¥ | ¥ 1,114,500 | ¥ 1,114,500 | ||
RMB [Member] | Retail Pharmaceutical Busines [Member] | ||||
Financial Assets Available for Sale (Textual) | ||||
Invested total amount | ¥ | 514,500 | |||
RMB [Member] | Songlu Pharmaceutical [Member] | ||||
Financial Assets Available for Sale (Textual) | ||||
Invested total amount | ¥ | ¥ 600,000 |
Trade Accounts Receivable (Deta
Trade Accounts Receivable (Details) - USD ($) | Jun. 30, 2020 | Mar. 31, 2020 |
Receivables [Abstract] | ||
Accounts receivable | $ 11,378,909 | $ 12,034,726 |
Less: allowance for doubtful accounts | (2,394,314) | (2,264,070) |
Trade accounts receivable, net | $ 8,984,595 | $ 9,770,656 |
Trade Accounts Receivable (De_2
Trade Accounts Receivable (Details Textual) - USD ($) | 3 Months Ended | ||
Jun. 30, 2020 | Jun. 30, 2019 | Mar. 31, 2020 | |
Trade Accounts Receivable (Textual) | |||
Accounts receivable written off | $ 26,834 | $ 36,068 | |
Trade accounts receivable pledged as collateral for borrowings | $ 515,771 | $ 627,055 |
Other Current Assets (Details)
Other Current Assets (Details) - USD ($) | Jun. 30, 2020 | Mar. 31, 2020 | |
Other Current Assets [Abstract] | |||
Rental deposits | [1] | $ 1,558,965 | $ 1,364,975 |
Prepaid and other current assets | 276,962 | 163,565 | |
Total | $ 1,835,927 | $ 1,528,540 | |
[1] | The balance as of June 30, 2020 and March 31, 2020 includes short-term refundable rental security deposits. |
Property and Equipment (Details
Property and Equipment (Details) - USD ($) | Jun. 30, 2020 | Mar. 31, 2020 | |
Property, Plant and Equipment [Line Items] | |||
Total | $ 23,081,361 | $ 22,913,475 | |
Less: Accumulated depreciation | (13,758,940) | (13,059,852) | |
Impairment | [1] | (2,226,731) | (2,219,883) |
Property and equipment, net | 7,095,690 | 7,633,740 | |
Building [Member] | |||
Property, Plant and Equipment [Line Items] | |||
Total | 5,898,768 | 5,880,627 | |
Leasehold improvements [Member] | |||
Property, Plant and Equipment [Line Items] | |||
Total | 9,397,190 | 9,209,136 | |
Farmland development cost [Member] | |||
Property, Plant and Equipment [Line Items] | |||
Total | 1,691,632 | 1,686,430 | |
Office equipment and furniture [Member] | |||
Property, Plant and Equipment [Line Items] | |||
Total | 5,587,888 | 5,632,955 | |
Motor vehicles [Member] | |||
Property, Plant and Equipment [Line Items] | |||
Total | $ 505,883 | $ 504,327 | |
[1] | The variance of impairment from March 31, 2020 to June 30, 2020 is solely caused by exchange rate variance. |
Property and Equipment (Detai_2
Property and Equipment (Details Textual) - USD ($) | 3 Months Ended | |
Jun. 30, 2020 | Jun. 30, 2019 | |
Property and Equipment (Textual) | ||
Depreciation expenses for property and equipment | $ 695,151 | $ 441,559 |
Long-Term Investment (Details)
Long-Term Investment (Details) - USD ($) | Jun. 30, 2020 | Mar. 31, 2020 | |
Advance to suppliers, net | $ 3,963,758 | $ 2,544,451 | |
Kahamadi Bio [Member] | |||
Advance to suppliers, net | [1] | 3,214 | 6,217 |
Zhetong Medical [Member] | |||
Advance to suppliers, net | [2] | $ 3,960,544 | $ 2,538,234 |
[1] | It represents 49% investment in Kahamadi Bio. The investment is recorded using the equity method. Kahamadi Bio suffered loss of $3,015 the three months ended June 30, 2020. | ||
[2] | It represents 39% investment in Zhejiang Zhetong Medical Co., Ltd. Zhetong Medical was established in March 2020 to target potential acquisitions or cooperate with local pharmacies. By attracting more funds from local investors, the Company expects to continue growing its local network in the future. |
Long-Term Investment (Details T
Long-Term Investment (Details Textual) | 6 Months Ended |
Jun. 30, 2020USD ($) | |
Kahamadi Bio [Member] | |
Long-Term Investment (Textual) | |
Investment percentage | 49.00% |
Suffered loss | $ 3,015 |
Zhetong Medical [Member] | |
Long-Term Investment (Textual) | |
Investment percentage | 39.00% |
Advances to Suppliers (Details)
Advances to Suppliers (Details) - USD ($) | Jun. 30, 2020 | Mar. 31, 2020 |
Advances to Suppliers [Abstract] | ||
Advance to suppliers | $ 3,160,046 | $ 2,198,863 |
Less: allowance for unrefundable advances | (922,326) | (1,024,063) |
Advance to suppliers, net | $ 2,237,720 | $ 1,174,800 |
Inventory (Details)
Inventory (Details) - USD ($) | Jun. 30, 2020 | Mar. 31, 2020 |
Inventory (Textual) | ||
Finished goods | $ 11,141,411 | $ 12,247,004 |
Farmland Assets (Details)
Farmland Assets (Details) - USD ($) | Jun. 30, 2020 | Mar. 31, 2020 | |
Farmland Assets [Abstract] | |||
Farmland assets | $ 2,191,944 | $ 2,177,606 | |
Less: Impairment | [1] | (1,439,687) | (1,435,259) |
Farmland assets, net | $ 752,257 | $ 742,347 | |
[1] | As of March 31, 2018, the book value of the Ginkgo trees planted in Qianhong Agriculture's farmland, including their cultivation cost and land lease amortization expense, was approximately $2,416,839. Based on an independent appraisal report, the value of the Ginkgo trees was approximately $796,286 as of March 31, 2018. As a result, the Company recorded an agricultural inventory impairment of $1,620,553 as of March 31, 2018. The difference between the recorded impairment loss and impairment balance in the above is primarily due to the exchange rate variance over years. There are no leasehold impairment expense in the three months ended June 30, 2020 and 2019. |
Farmland Assets (Details Textua
Farmland Assets (Details Textual) | 3 Months Ended |
Mar. 31, 2018USD ($) | |
Farmland Assets (Textual) | |
Inventory impairment | $ 1,620,553 |
Qianhong Agriculture’s farmland [Member] | |
Farmland Assets (Textual) | |
Amortization expense | 2,416,839 |
Ginkgo trees [Member] | |
Farmland Assets (Textual) | |
Amortization expense | $ 796,286 |
Long Term Refundable Deposits_2
Long Term Refundable Deposits, Landlords (Details) - USD ($) | Jun. 30, 2020 | Mar. 31, 2020 |
Long Term Deposits, Landlords [Abstract] | ||
Long term deposits | $ 1,447,547 | $ 1,456,384 |
Other Noncurrent Assets (Detail
Other Noncurrent Assets (Details) - USD ($) | Jun. 30, 2020 | Mar. 31, 2020 | |
Other Assets, Noncurrent Disclosure [Abstract] | |||
Forest land use rights | [1] | $ 985,156 | $ 994,558 |
Others | 64,028 | 52,205 | |
Total | $ 1,049,184 | $ 1,046,763 | |
[1] | The prepayment for lease of forest land use rights is a payment made to a local government in connection with entering into an operating land lease agreement. The land is currently used to cultivate Ginkgo trees. The forest rights certificate from the local village extends the life of the lease to January 31, 2060. |
Other Noncurrent Assets (Deta_2
Other Noncurrent Assets (Details 1) | Jun. 30, 2020USD ($) |
Other Assets, Noncurrent Disclosure [Abstract] | |
2021 | $ 26,515 |
2022 | 26,515 |
2023 | 26,515 |
2024 | 26,515 |
2025 | 26,515 |
Thereafter | $ 852,581 |
Other Noncurrent Assets (Deta_3
Other Noncurrent Assets (Details Textual) - USD ($) | 3 Months Ended | |
Jun. 30, 2020 | Jun. 30, 2019 | |
Other Noncurrent Assets (Textual) | ||
Amortization of prepayment for lease of land use right | $ 12,441 | $ 6,885 |
Description of lease prepayment life | Extends the life of the lease to January 31, 2060. |
Leases (Details)
Leases (Details) | Jun. 30, 2020USD ($) |
Cash paid for amounts included in the measurement of lease liabilities: | |
Operating cash flows paid for operating leases | $ 1,671,118 |
Right-of-use assets obtained in exchange for lease obligations: | |
Operating leases |
Leases (Details 1)
Leases (Details 1) - USD ($) | Jun. 30, 2020 | Mar. 31, 2020 |
Operating leases: | ||
Operating lease right-of-use assets | $ 19,351,247 | $ 21,711,376 |
Current portion of operating lease liabilities | 466,213 | 981,090 |
Long-term operating lease liabilities | 16,917,159 | $ 19,049,575 |
Total operating lease liabilities | $ 17,383,372 | |
Weighted average remaining lease term, Operating leases | 3 years 2 months 12 days | |
Weighted average discount rate, Operating leases | 4.19% |
Leases (Details 2)
Leases (Details 2) | Jun. 30, 2020USD ($) |
Leases [Abstract] | |
2021 | $ 485,355 |
2022 | 6,345,189 |
2023 | 4,510,762 |
2024 | 3,277,971 |
2025 | 1,995,568 |
Thereafter | 2,575,035 |
Total lease payments | 19,189,880 |
Less: imputed interest | (1,806,508) |
Total lease liabilities | $ 17,383,372 |
Leases (Details Textual)
Leases (Details Textual) | 3 Months Ended |
Jun. 30, 2020USD ($) | |
Leases (Textual) | |
Operating lease cost | $ 1,671,118 |
Minimum [Member] | |
Leases (Textual) | |
Operating lease initial terms | 3 years |
Maximum [Member] | |
Leases (Textual) | |
Operating lease initial terms | 10 years |
Intangible Assets (Details)
Intangible Assets (Details) - USD ($) | Jun. 30, 2020 | Mar. 31, 2020 | |
Acquired Finite-Lived Intangible Assets [Line Items] | |||
Total intangible assets | $ 4,712,583 | $ 4,678,631 | |
Less: accumulated amortization | (735,234) | (667,633) | |
Less: impairment | [1] | (618,942) | (617,038) |
Intangible assets, net | 3,358,407 | 3,393,960 | |
License [Member] | |||
Acquired Finite-Lived Intangible Assets [Line Items] | |||
Total intangible assets | [2] | 2,246,880 | 2,220,512 |
Software [Member] | |||
Acquired Finite-Lived Intangible Assets [Line Items] | |||
Total intangible assets | [3] | 1,086,366 | 1,083,024 |
Land use rights [Member] | |||
Acquired Finite-Lived Intangible Assets [Line Items] | |||
Total intangible assets | [4] | $ 1,379,337 | $ 1,375,095 |
[1] | In the year ended March 31, 2020, the company evaluated the licenses of insurance applicable drugstores acquired in the past based on the discounted positive cash value. Due to the stricter government insurance policy in fiscal year 2021, the value of these licenses has declined. As a result, the company recorded an impairment. There are no impairment expense in the three months ended June 30, 2020 and 2019. | ||
[2] | This represents the fair value of the licenses of insurance applicable drugstores acquired from a variety of drugstores such as Sanhao Pharmacy and several local stores. The licenses allow patients to pay by using insurance cards at stores. The stores are reimbursed from the Human Resource and Social Security Department of Hangzhou City. In 2014, the Company acquired Sanhao Pharmacy, a drugstore chain. In September 2017, the Company acquired several new stores for the purpose of the Municipal Social Medical Reimbursement Qualification Certificates. On January 9, 2020, the Company acquired a local drugstore chain. The acquired drugstores ceased their stores' business and liquidate all of the stores' accounts after Jiuzhou Pharmacy acquired them. In March 2020, the drugstore chain has dissolved and its certificates were transferred to new stores opened at the same time. | ||
[3] | These balances primarily include the SAP ERP system, the Internet Clinic Diagnosis Terminal system and the Chronic Disease Management system. In 2017, we have installed a leading ERP system, SAP from Germany. SAP is a well-known management system used by many fortune 500 companies. It is being amortized over three years since its installation. In 2020, we have installed an internet Clinic Diagnosis System used to strengthen our ability to perform online diagnosis which may increase more customer spending and a Chronic Disease Management System used to better manage and monitor our members' health. As of June 30, 2020, the SAP system has a net value of $135,698 (RMB 959,352), the internet Clinic Diagnosis System has a net value of approximately $380,313 (RMB 2,688,709), the Chronic Disease Management System has a net value of approximately $16,462 (RMB 116,379) . | ||
[4] | In July 2013, the Company purchased the land use rights of a plot of land in Lin'an, Hangzhou, intended for the establishment of an herb processing plant in the future. However, as the Company's farming business in Lin'an has not grown, the Company does not expect completion of the plant in the near future. |
Intangible Assets (Details Text
Intangible Assets (Details Textual) | 3 Months Ended | |||
Jun. 30, 2020USD ($) | Jun. 30, 2020CNY (¥) | Jun. 30, 2019USD ($) | Jun. 30, 2020CNY (¥) | |
Intangible Assets (Textual) | ||||
Amortization expense | $ 65,389 | $ 58,466 | ||
Internet Clinic Diagnosis System [Member] | ||||
Intangible Assets (Textual) | ||||
Amortization expense | 135,698 | |||
Intangible assets, net | 380,313 | |||
Internet Clinic Diagnosis System [Member] | RMB [Member] | ||||
Intangible Assets (Textual) | ||||
Amortization expense | ¥ | ¥ 959,352 | |||
Intangible assets, net | ¥ | ¥ 2,688,709 | |||
Chronic Disease Costs [Member] | ||||
Intangible Assets (Textual) | ||||
Amortization expense | $ 16,462 | |||
Chronic Disease Costs [Member] | RMB [Member] | ||||
Intangible Assets (Textual) | ||||
Amortization expense | ¥ | ¥ 116,379 |
Notes Payable (Details)
Notes Payable (Details) - USD ($) | 3 Months Ended | |||
Jun. 30, 2020 | Mar. 31, 2020 | Mar. 30, 2020 | ||
Short-term Debt [Line Items] | ||||
Notes payable | [1] | $ 26,715,374 | $ 26,605,971 | |
Hangzhou United Bank [Member] | Jiuzhou Pharmacy [Member] | 10/09/19 [Member] | ||||
Short-term Debt [Line Items] | ||||
Maturity date | [1] | Apr. 9, 2020 | ||
Notes payable | [1] | 3,478,259 | $ 3,478,259 | |
Hangzhou United Bank [Member] | Jiuzhou Pharmacy [Member] | 11/06/19 [Member] | ||||
Short-term Debt [Line Items] | ||||
Maturity date | [1] | May 6, 2020 | ||
Notes payable | [1] | 164,582 | ||
Hangzhou United Bank [Member] | Jiuzhou Pharmacy [Member] | 12/05/19 [Member] | ||||
Short-term Debt [Line Items] | ||||
Maturity date | [1] | Jun. 5, 2020 | ||
Notes payable | [1] | 3,106,474 | ||
Hangzhou United Bank [Member] | Jiuzhou Pharmacy [Member] | 12/31/19 [Member] | ||||
Short-term Debt [Line Items] | ||||
Maturity date | [1] | Jun. 30, 2020 | ||
Notes payable | [1] | |||
Hangzhou United Bank [Member] | Jiuzhou Pharmacy [Member] | 01/06/20 [Member] | ||||
Short-term Debt [Line Items] | ||||
Maturity date | [1] | Jul. 6, 2020 | ||
Notes payable | [1] | $ 129,856 | 129,457 | |
Hangzhou United Bank [Member] | Jiuzhou Pharmacy [Member] | 02/19/20 [Member] | ||||
Short-term Debt [Line Items] | ||||
Maturity date | [1] | Aug. 19, 2020 | ||
Notes payable | [1] | $ 5,120,844 | 5,105,096 | |
Hangzhou United Bank [Member] | Jiuzhou Pharmacy [Member] | 12/31/19 [Member] | ||||
Short-term Debt [Line Items] | ||||
Maturity date | [1] | Jun. 30, 2020 | ||
Notes payable | [1] | 129,457 | ||
Hangzhou United Bank [Member] | Jiuzhou Pharmacy [Member] | 03/31/20 [Member] | ||||
Short-term Debt [Line Items] | ||||
Maturity date | [1] | Sep. 30, 2020 | ||
Notes payable | [1] | $ 1,697,376 | 1,692,156 | |
Hangzhou United Bank [Member] | Jiuzhou Pharmacy [Member] | 04/10/20 [Member] | ||||
Short-term Debt [Line Items] | ||||
Maturity date | [1] | Oct. 10, 2020 | ||
Notes payable | [1] | $ 2,969,129 | ||
Hangzhou United Bank [Member] | Jiuzhou Pharmacy [Member] | 04/29/20 [Member] | ||||
Short-term Debt [Line Items] | ||||
Maturity date | [1] | Oct. 29, 2020 | ||
Notes payable | [1] | $ 546,874 | ||
Hangzhou United Bank [Member] | Jiuzhou Pharmacy [Member] | 05/09/20 [Member] | ||||
Short-term Debt [Line Items] | ||||
Maturity date | [1] | Nov. 9, 2020 | ||
Notes payable | [1] | $ 3,803,552 | ||
Hangzhou United Bank [Member] | Jiuzhou Pharmacy [Member] | 11/06/18 [Member] | ||||
Short-term Debt [Line Items] | ||||
Maturity date | [1] | Apr. 9, 2020 | ||
Notes payable | [1] | |||
Hangzhou United Bank [Member] | Jiuzhou Pharmacy [Member] | 11/06/19 [Member] | ||||
Short-term Debt [Line Items] | ||||
Maturity date | [1] | May 6, 2020 | ||
Notes payable | [1] | 164,582 | ||
Hangzhou United Bank [Member] | Jiuzhou Pharmacy [Member] | 12/05/19 [Member] | ||||
Short-term Debt [Line Items] | ||||
Maturity date | [1] | Jun. 5, 2020 | ||
Notes payable | [1] | 3,106,474 | ||
Hangzhou United Bank [Member] | Jiuzhou Pharmacy [Member] | 06/30/20 [Member] | ||||
Short-term Debt [Line Items] | ||||
Maturity date | [1] | Dec. 30, 2020 | ||
Notes payable | [1] | $ 4,809,329 | ||
Hangzhou United Bank [Member] | Jiuzhou Pharmacy [Member] | 12/31/19 [Member] | ||||
Short-term Debt [Line Items] | ||||
Maturity date | [1] | Jun. 30, 2020 | ||
Notes payable | [1] | 3,943,776 | ||
Hangzhou United Bank [Member] | Jiuzhou Pharmacy [Member] | 06/24/20 [Member] | ||||
Short-term Debt [Line Items] | ||||
Maturity date | [1] | Dec. 24, 2020 | ||
Notes payable | [1] | $ 1,405,995 | ||
Hangzhou United Bank [Member] | Jiuzhou Pharmacy [Member] | 06/30/20 [Member] | ||||
Short-term Debt [Line Items] | ||||
Maturity date | [1] | Dec. 30, 2020 | ||
Notes payable | [1] | $ 891,122 | ||
Hangzhou United Bank [Member] | Jiuxin Medicine [Member] | 03/10/20 [Member] | ||||
Short-term Debt [Line Items] | ||||
Maturity date | [1] | Sep. 10, 2020 | ||
Notes payable | [1] | $ 5,341,297 | 5,324,871 | |
Hangzhou United Bank [Member] | Jiuxin Medicine [Member] | 12/26/19 [Member] | ||||
Short-term Debt [Line Items] | ||||
Maturity date | [1] | Jun. 26, 2020 | ||
Notes payable | [1] | |||
Hangzhou United Bank [Member] | Jiuxin Medicine [Member] | 04/29/20 [Member] | ||||
Short-term Debt [Line Items] | ||||
Maturity date | [1] | Sep. 20, 2020 | ||
Notes payable | [1] | 1,692,156 | ||
Hangzhou United Bank [Member] | Jiuxin Medicine [Member] | 12/26/19 [Member] | ||||
Short-term Debt [Line Items] | ||||
Maturity date | [1] | Jun. 26, 2020 | ||
Notes payable | [1] | 1,371,992 | ||
Hangzhou United Bank [Member] | Jiuxin Medicine [Member] | 12/31/19 [Member] | ||||
Short-term Debt [Line Items] | ||||
Maturity date | [1] | Jun. 30, 2020 | ||
Notes payable | [1] | $ 3,943,776 | ||
[1] | As of June 30, 2020, the Company had $26,715,374 (RMB 188,870,639) of notes payable from HUB. The Company is required to hold restricted cash in the amount of $14,913,825 (RMB 105,684,113) with HUB as collateral against these bank notes. Included in the restricted cash is a total of $8,770,422 three-year deposit (RMB 62,150,000) deposited into HUB as a collateral for current and future notes payable from HUB. As of March 31, 2020, the Company had $26,605,971 (RMB 188,677,437) of notes payable from HUB. The Company is required to hold restricted cash in the amount of $14,596,179 (RMB 103,509,456) with HUB as collateral against these bank notes. Included in the restricted cash is a total of $8,763,958 three-year deposit (RMB 62,150,000) deposited into HUB as a collateral for current and future notes payable from HUB. |
Notes Payable (Details Textual)
Notes Payable (Details Textual) | 3 Months Ended | |||
Jun. 30, 2020USD ($) | Jun. 30, 2020CNY (¥) | Mar. 31, 2020USD ($) | Mar. 31, 2020CNY (¥) | |
Notes Payable (Textual) | ||||
Notes payable | $ 26,720,000 | |||
Restricted cash | 6,140,000 | |||
Line of credit total | 27,460,000 | |||
Bank credit line facilities available for borrowing | $ 740,000 | |||
Term of deposit | 3 years | |||
Deposit amount | $ 8,770,000 | |||
Hangzhou United Bank One [Member] | Notes Payable to Banks [Member] | ||||
Notes Payable (Textual) | ||||
Restricted cash | $ 8,770,422 | $ 8,763,958 | ||
Term of deposit | 3 years | |||
Hangzhou United Bank One [Member] | Notes Payable to Banks [Member] | RMB [Member] | ||||
Notes Payable (Textual) | ||||
Restricted cash | ¥ | ¥ 62,150,000 | ¥ 62,150,000 | ||
Hangzhou United Bank [Member] | ||||
Notes Payable (Textual) | ||||
Bank credit line facilities available for borrowing | $ 12,550,000 | |||
Hangzhou United Bank [Member] | Notes Payable to Banks [Member] | ||||
Notes Payable (Textual) | ||||
Notes payable | 26,715,374 | 26,605,971 | ||
Restricted cash | $ 14,913,825 | $ 14,596,179 | ||
Hangzhou United Bank [Member] | Notes Payable to Banks [Member] | RMB [Member] | ||||
Notes Payable (Textual) | ||||
Notes payable | ¥ | 188,870,639 | 188,677,437 | ||
Restricted cash | ¥ | ¥ 105,684,113 | ¥ 103,509,456 |
Loan Payable (Details)
Loan Payable (Details) - USD ($) | 3 Months Ended | |||
Jun. 30, 2020 | Mar. 31, 2020 | Dec. 11, 2019 | Aug. 02, 2019 | |
Loan Payable (Textual) | ||||
Borrowing amount | $ 6,460,290 | $ 717,810 | ||
Remaining loan balance | $ 5,851,778 | |||
Monthly repayment due | $ 2,300,271 | $ 2,287,742 | ||
Refundable loan received amount | $ 5,878,864 | $ 617,317 |
Taxes (Details)
Taxes (Details) - USD ($) | 3 Months Ended | |
Jun. 30, 2020 | Jun. 30, 2019 | |
Taxes (Textual) | ||
Effective tax rate | (17.40%) | (0.40%) |
Unrecognized tax benefits | $ 0 |
Postretirement Benefits (Detail
Postretirement Benefits (Details) - USD ($) | 3 Months Ended | |
Jun. 30, 2020 | Jun. 30, 2019 | |
Employee Social Benefits (Textual) | ||
Employment benefits and pension contribution | $ 204,538 | $ 341,024 |
Related Party Transactions an_3
Related Party Transactions and Arrangements (Details) - USD ($) | Jun. 30, 2020 | Mar. 31, 2020 | |
Due to a director and CEO [Member] | |||
Related Party Transaction [Line Items] | |||
Total | [1] | $ 491,300 | $ 490,218 |
[1] | Due to foreign exchange restrictions, the Company's director and CEO, Mr. Lei Liu personally lent U.S. dollars to the Company to facilitate its payments of expenses in the United States. |
Related Party Transactions an_4
Related Party Transactions and Arrangements (Details Textual) | 1 Months Ended | 3 Months Ended | ||
Apr. 28, 2018USD ($) | Apr. 28, 2018CNY (¥) | Jun. 30, 2020USD ($) | Jun. 30, 2019USD ($) | |
Chief Executive Officer [Member] | ||||
Related Party Transactions and Arrangements (Textual) | ||||
Lease expiration date | Sep. 30, 2020 | |||
Rent expenses | $ 6,532 | $ 6,785 | ||
Ownership percentage | 51.00% | 51.00% | ||
Hangzhou Kangzhou Biotech [Member] | ||||
Related Party Transactions and Arrangements (Textual) | ||||
Total proceeds | $ 75,643 | |||
Sale of percentage | 10.00% | 10.00% | ||
Hangzhou Kangzhou Biotech [Member] | CNY [Member] | ||||
Related Party Transactions and Arrangements (Textual) | ||||
Total proceeds | ¥ | ¥ 507,760 |
Warrants (Details)
Warrants (Details) - Common Stock Warrants [Member] - $ / shares | 3 Months Ended | 12 Months Ended |
Jun. 30, 2020 | Mar. 31, 2020 | |
Class of Warrant or Right [Line Items] | ||
Stock price | $ 1.44 | $ 1.77 |
Exercise price | $ 3.10 | $ 3.10 |
Annual dividend yield | ||
Expected term (years) | 6 months 21 days | 9 months 22 days |
Risk-free interest rate | 0.18% | 0.71% |
Expected volatility | 98.86% | 62.08% |
Warrants (Details Textual)
Warrants (Details Textual) - USD ($) | 1 Months Ended | 3 Months Ended | 12 Months Ended | |||
Jul. 19, 2015 | Jun. 30, 2020 | Jun. 30, 2019 | Mar. 31, 2020 | Mar. 31, 2019 | Jun. 01, 2020 | |
Warrants (Textual) | ||||||
Fair value estimation method | Binominal pricing model | |||||
Stock purchase price per share (in dollars per share) | $ 3.10 | |||||
Purchase of warrants investors | 647,000 | 672,000 | ||||
Purchase option and warrants liability | $ 68,980 | $ 64,090 | ||||
Exercise of warrants | 25,000 | |||||
Warrant [Member] | ||||||
Warrants (Textual) | ||||||
Stock purchase price per share (in dollars per share) | $ 3.10 | $ 3.10 | ||||
Warrants exercisable date | Jan. 19, 2016 | |||||
Maturity date | Jan. 18, 2021 | |||||
Purchase of warrants investors | 600,000 | |||||
Fair value of warrant liability investor placement agent | $ 68,980 | |||||
Issuance of warrants to placement agent | 72,000 | |||||
Percentage of stock sold in offering | 6.00% | |||||
Change in fair value of warrants liability | $ 4,890 | $ 403,555 | ||||
Exercise of warrants | 647,000 | 25,000 |
Employee Deposits (Details)
Employee Deposits (Details) | Jun. 30, 2020USD ($) | Jun. 30, 2020CNY (¥) | Mar. 31, 2020USD ($) | Mar. 31, 2020CNY (¥) |
Financial Liability (Textual) | ||||
Reclassifies deposits financial liability | $ | $ 14,145 | $ 70,507 | ||
RMB [Member] | ||||
Financial Liability (Textual) | ||||
Reclassifies deposits financial liability | ¥ | ¥ 100,000 | ¥ 500,000 |
Stockholder's Equity (Details)
Stockholder's Equity (Details) | Jun. 03, 2020$ / sharesshares | Nov. 18, 2014Individuals$ / sharesshares | Apr. 15, 2019USD ($)$ / sharesshares | Jun. 30, 2020shares | Jun. 01, 2020$ / sharesshares | Mar. 31, 2020shares |
Stockholder's Equity (Textual) | ||||||
Reserve fund percentage | 50.00% | |||||
Statutory accounts percentage | 10.00% | |||||
Exercise of warrants | 25,000 | |||||
Warrants per share | $ / shares | $ 3.10 | |||||
Issued of common stock | 37,961,790 | 25,000 | 32,936,786 | |||
Stockholder's equity, description | The Company closed a registered direct offering of 5,000,004 shares of common stock at $2.00 per share with gross proceeds of $10,000,008 from its effective shelf registration statement. | |||||
Common Stock [Member] | ||||||
Stockholder's Equity (Textual) | ||||||
Exercise price of stock option | $ / shares | $ 2.57 | $ 3.125 | ||||
Warrants to purchase | 300,000 | 240,000 | ||||
Common Stock [Member] | Investor [Member] | ||||||
Stockholder's Equity (Textual) | ||||||
Common stock, par value | $ / shares | $ 2.50 | |||||
Proceeds from private placement | $ | $ 10,000,020 | |||||
Warrants to purchase | 4,000,008 | |||||
Purchase price per share | $ / shares | $ 2.20 | |||||
Common Stock [Member] | Investor [Member] | ||||||
Stockholder's Equity (Textual) | ||||||
Warrants to purchase | 3,750,003 | 3,000,006 | ||||
Aggregate purchase of number of shares | 6.50% | 6.00% | ||||
Employee Stock Option [Member] | ||||||
Stockholder's Equity (Textual) | ||||||
Number of granted shares | 967,000 | |||||
Number of directors, officers and employees in a group | Individuals | 46 | |||||
Exercise price of stock option | $ / shares | $ 2.50 | |||||
Period for options exercisable from the vesting date | 5 years | |||||
Maturity date | Nov. 17, 2022 |
Loss Per Share (Details)
Loss Per Share (Details) - USD ($) | 3 Months Ended | |
Jun. 30, 2020 | Jun. 30, 2019 | |
LOSS PER SHARES: | ||
Net loss attributable to controlling interest | $ (231,509) | $ (2,134,951) |
Weighted average shares used in basic computation | 34,428,271 | 32,453,269 |
Diluted effect of stock options and warrants | ||
Weighted average shares used in diluted computation | 34,428,271 | 32,453,269 |
Loss per share – Basic: | ||
Net loss attributable to controlling interest | $ (0.01) | $ (0.07) |
Loss per share – Diluted: | ||
Net loss attributable to controlling interest | $ (0.01) | $ (0.07) |
Loss Per Share (Details Textual
Loss Per Share (Details Textual) - Employee Stock Option [Member] | 3 Months Ended |
Jun. 30, 2020shares | |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | |
Antidilutive securities excluded from calculation of diluted earnings per share | 967,000 |
Private Placement [Member] | |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | |
Antidilutive securities excluded from calculation of diluted earnings per share | 72,000 |
Investor [Member] | |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | |
Antidilutive securities excluded from calculation of diluted earnings per share | 575,000 |
Segments (Details)
Segments (Details) - USD ($) | 3 Months Ended | |
Jun. 30, 2020 | Jun. 30, 2019 | |
Revenue | $ 31,054,312 | $ 25,280,784 |
Cost of goods | 23,074,093 | 19,219,346 |
Gross profit | 7,980,219 | 6,061,438 |
Selling expenses | 6,272,407 | 5,968,551 |
General and administrative expenses | 2,120,166 | 2,851,612 |
Loss from operations | (412,354) | (2,758,725) |
Depreciation and amortization | 760,540 | 512,949 |
Total capital expenditures | 169,807 | 753,173 |
Retail drugstores [Member] | ||
Revenue | 18,810,474 | 16,734,988 |
Cost of goods | 12,402,182 | 11,682,721 |
Gross profit | 6,408,292 | 5,052,267 |
Selling expenses | 4,977,047 | 4,835,666 |
General and administrative expenses | 1,128,083 | 1,733,704 |
Loss from operations | 303,162 | (1,517,103) |
Depreciation and amortization | 750,498 | 504,463 |
Total capital expenditures | 169,807 | 753,173 |
Online Pharmacy [Member] | ||
Revenue | 4,912,834 | 2,443,605 |
Cost of goods | 4,228,411 | 2,096,850 |
Gross profit | 684,423 | 346,755 |
Selling expenses | 704,876 | 473,380 |
General and administrative expenses | 59,011 | 55,123 |
Loss from operations | (79,464) | (181,748) |
Depreciation and amortization | ||
Total capital expenditures | ||
Drug Wholesale [Member] | ||
Revenue | 7,331,004 | 6,102,191 |
Cost of goods | 6,443,500 | 5,439,775 |
Gross profit | 887,504 | 662,416 |
Selling expenses | 590,484 | 659,505 |
General and administrative expenses | 933,072 | 1,062,785 |
Loss from operations | (636,052) | (1,059,874) |
Depreciation and amortization | 10,042 | 8,486 |
Herbs Farming [Member] | ||
Revenue | ||
Cost of goods | ||
Gross profit | ||
Selling expenses | ||
General and administrative expenses | ||
Loss from operations | ||
Depreciation and amortization | ||
Total capital expenditures |
Segments (Details 1)
Segments (Details 1) - USD ($) | 3 Months Ended | |
Jun. 30, 2020 | Jun. 30, 2019 | |
Net revenue from external customers | $ 31,054,312 | $ 25,280,784 |
Retail Drugstores [Member] | ||
Net revenue from external customers | 7,331,004 | 6,102,191 |
Retail Drugstores [Member] | Prescription Drugs [Member] | ||
Net revenue from external customers | 7,406,774 | 5,695,286 |
Retail Drugstores [Member] | OTC Drugs [Member] | ||
Net revenue from external customers | 6,818,484 | 7,240,228 |
Retail Drugstores [Member] | Nutritional Supplements [Member] | ||
Net revenue from external customers | 1,347,769 | 1,231,133 |
Retail Drugstores [Member] | TCM [Member] | ||
Net revenue from external customers | 949,012 | 1,104,050 |
Retail Drugstores [Member] | Sundry Products [Member] | ||
Net revenue from external customers | 422,551 | 298,198 |
Retail Drugstores [Member] | Medical Devices [Member] | ||
Net revenue from external customers | 1,865,884 | 1,166,093 |
Online Pharmacy [Member] | ||
Net revenue from external customers | 4,912,834 | 2,443,605 |
Online Pharmacy [Member] | Prescription Drugs [Member] | ||
Net revenue from external customers | 1,869,643 | |
Online Pharmacy [Member] | OTC Drugs [Member] | ||
Net revenue from external customers | 1,322,811 | 1,024,602 |
Online Pharmacy [Member] | Nutritional Supplements [Member] | ||
Net revenue from external customers | 221,031 | 107,194 |
Online Pharmacy [Member] | TCM [Member] | ||
Net revenue from external customers | 23,199 | 13,681 |
Online Pharmacy [Member] | Sundry Products [Member] | ||
Net revenue from external customers | 546,720 | 438,736 |
Online Pharmacy [Member] | Medical Devices [Member] | ||
Net revenue from external customers | 929,430 | 859,392 |
Wholesale [Member] | ||
Net revenue from external customers | 7,331,004 | 6,102,191 |
Wholesale [Member] | Prescription Drugs [Member] | ||
Net revenue from external customers | 5,966,148 | 4,880,491 |
Wholesale [Member] | OTC Drugs [Member] | ||
Net revenue from external customers | 915,146 | 1,074,261 |
Wholesale [Member] | Nutritional Supplements [Member] | ||
Net revenue from external customers | 59,841 | 21,691 |
Wholesale [Member] | TCM [Member] | ||
Net revenue from external customers | 28,967 | 98,828 |
Wholesale [Member] | Sundry Products [Member] | ||
Net revenue from external customers | 2,597 | 5,682 |
Wholesale [Member] | Medical Devices [Member] | ||
Net revenue from external customers | $ 358,305 | $ 21,238 |
Segments (Details Textual)
Segments (Details Textual) | 3 Months Ended |
Jun. 30, 2020Segment | |
Segments (Textual) | |
Number of operating segments | 4 |